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Acute lower respiratory tract infections (ALRI) are a substantial source of global 
morbidity and mortality, particularly among young children. Respiratory syncytial virus (RSV) 
and influenza are consistently observed to be significant drivers of this burden, but substantial 
gaps in our understanding remain. Greater understanding of the burden of these pathogens at the 
community-level, and their association with severe illness has the potential to substantially 
reduce the toll of ALRI, particularly among young children.  
In chapter 2 of this dissertation we assess the community burden of RSV and RSV-
associated severe illness among Nicaraguan children aged < 2 years. In chapters 3 and 4 we 
explore the individual-level association between influenza and subsequent pneumonia along with 
characterizing the risk period for pneumonia following symptomatic influenza infection. To 
explore these questions we use data from the Nicaragua Influenza Birth Cohort Study (2011-
2016), the Nicaraguan Pediatric Influenza Cohort Study (2011-2018), and the Nicaragua 
Influenza Cohort Study (2007-2010). 
In chapter 2 we observed the highest incidence of RSV occurred among children aged 6-
11 months, while the highest incidence of RSV-associated severe ALRI was highest among those 
aged < 3 months and generally decreased as age increased. RSV was also associated with at least 
25% of illness deaths that occurred in the cohort, highlighting its importance in reducing in 
infant mortality. In chapters 3 and 4 we established that influenza is associated with increased 
risk of subsequent pneumonia at the individual level across types and subtypes with the 
exception of seasonal H1N1. We also observed distinct periods of elevated pneumonia risk 
 xvi 
following influenza among children aged <2 which is suggestive of multiple etiologic pathways 
existing between influenza and pneumonia. By better understanding the burden and temporal 
dynamics of RSV and influenza we can develop more effective interventions to prevent and 




Chapter 1  Introduction 
 
1.1 Burden of acute respiratory infections 
Acute lower respiratory infections (ALRI), like pneumonia and bronchiolitis, remain a 
significant source of morbidity and mortality worldwide, especially among young children.[1-3] 
In 2010 there were an estimated 11.9 million episodes of severe ALRI, and roughly 265,000 in 
hospital deaths among children under 5.[1] It is also estimated that in-hospital deaths represent 
only 19% of overall mortality bringing the total estimated mortality from ALRI among young 
children to roughly 1.4 million deaths each year.[4] In 2017, pneumonia alone was responsible 
for the deaths of over 800,000 children under five—15% of all deaths in this age group 
worldwide.[5] Additionally, the global burden is not evenly distributed, with an estimated 99% 
of ALRI-mortality occurring in developing countries.[1] Nicaragua is a prime example of this 
disparity as acute respiratory infections are the leading communicable cause of death for children 
under five.[6] While there are many respiratory viruses that cause illness in humans, respiratory 
syncytial virus (RSV) and influenza are substantial contributors to the overall burden of 
morbidity and mortality from ALRI, and thus are the focus of this dissertation.[7, 8] 
1.2 RSV 
1.2.1 History and burden 
First discovered in chimpanzees in 1956, RSV was initially named chimpanzee coryza 
agent (CCA) owing to its frequent presentation of rhinorrhea and nasal inflammation.[9] 
However, its isolation from infants with respiratory illness in 1957 led to a new name, 
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respiratory syncytial virus (RSV), a reference to the multinucleated syncytial giant cells caused 
by viral replication in bronchial epithelial cells.[9, 10] There are two known serotypes, A and B, 
with evidence showing RSVA viral loads are frequently higher than RSVB.[10, 11] RSV is also 
one of the most commonly occurring viral infections, with an estimated 97% of children having 
at least 1 infection by age 2.[12]  
RSV has been established as a significant source of morbidity and mortality among 
young children [2, 13, 14], the elderly[15, 16], and the immunocompromised.[17, 18] In 2015 
there were an estimated 33.1 million cases of RSV-ALRI among children under five worldwide, 
3.2 million of which were severe enough to require hospitalization.[2] That same year there were 
nearly 60,000 in-hospital deaths from RSV-ALRI, though the authors suggested that the overall 
mortality from RSV (including deaths occurring in the community) could be up to twice as 
high.[2] Despite this substantial burden, few options exist for the prevention or treatment of RSV 
illness. 
1.2.2 Treatment and prevention 
RSV has long been a target for vaccination, however, its ability to elicit such a strong 
host immune response has complicated efforts. In the 1960s clinical trials of a formalin-
inactivated RSV vaccine were conducted in which the vaccine was found to enhance RSV 
illness, contributing to the death of two study participants.[19-22] Vaccine efforts have continued 
since then, trying to strike a balance between inducing sufficient immunity while not causing 
enhanced disease.[19, 21] While some vaccine candidates have shown promise in early phases of 
clinical trials, none have yet met their phase 3 primary outcome and thus there are still not any 
licensed RSV vaccines. 
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Development of interventions to prevent RSV has not been limited to vaccines. 
Temporary protection during especially high-risk periods has been explored through the use of 
monocolonal antibodies (mAb) like Palivizuvab (Synagis®)—a monoclonal antibody to the RSV 
F-protein.[23, 24] Currently Palivizumab exists as the only market approved preventive measure 
for RSV[25], and the American Academy of Pediatrics recommends it be considered only for 
young children most susceptible to severe RSV illness (e.g. premature infants, 
immunocompromised).[26] Studies surrounding its cost-effectiveness are somewhat 
controversial as they rely heavily on cost-savings accrued over the life course from 
asthma/recurrent wheezing averted by preventing severe RSV infection.[26] Regardless, the 
substantial cost of the intervention, both monetarily and through repeated healthcare visits, 
places it beyond the reach of many low- and middle-income countries (LMICs), leaving 
essentially no viable preventative measures for RSV available in those countries. While 
preliminary results from several interventions in development appear promising, addressing gaps 
that persist in our understanding of risk factors for RSV will be crucial in mitigating the 
substantial burden associated with RSV until such a time when an effective treatment or 
preventative are available. These gaps in the literature are especially prevalent in LMICs where 
even basic information regarding seasonality, burden, and transmission remain unknown. 
1.2.3 Research gaps 
Given the sheer ubiquity of RSV, research on risk factors tends to focus on severe RSV 
illness (e.g. hospitalization, pneumonia)[27], and as such are frequently conducted in hospitals or 
other in-patient settings.[28-34] Such hospital-based studies on their own, fail to capture the 
overall RSV burden in a given population. While the number of community-based studies 
continues to grow, it still lags far behind that of hospital-based studies.[13, 14, 35] 
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Still, published studies have consistently shown an association between factors like 
prematurity, low birth weight, and comorbidities and severe RSV.[27] However, the paucity of 
community-based studies provides less opportunity to examine social and environmental factors 
that may contribute to children developing severe illness. In their 2015 review, Shi et al. call for 
an increase in “large-scale, high-quality multivariable studies” to improve understanding of the 
risk factors for severe RSV.[27] However, without addressing the imbalance between hospital 
and community-based studies, the role of social and environmental risk factors for severe RSV 
illness will remain poorly understood.  
1.3 Influenza 
1.3.1 History and Burden 
Influenza refers to a group of single-stranded RNA viruses in the 
Orthomyxoviridae family of which influenza types A and B commonly infect humans.[36, 37] 
Until the viruses were first isolated in the 1930s, little was known about the pathogen responsible 
for influenza illness, with some mistakenly attributing it to a bacterium (particularly 
Haemophilus influenzae as evident in its name).[36, 38, 39] Influenza A was isolated first by 
researchers in the United Kingdom [38], while influenza B was isolated soon after by Thomas 
Francis at the University of Michigan.[39]   
Influenza A viruses are classified into subtypes based on two surface proteins on the 
virus: hemagglutinin and neuraminidase.[37] These are abbreviated (H for hemagglutinin and N 
for neuraminidase), numbered (H:1-18 and N:1-11), and combined giving rise to familiar 
subtypes like H1N1 or H3N2.[37] While H1N1 and H3N2 are the subtypes currently causing 
seasonal epidemics, other subtypes, particularly avian subtypes like H7N9 and H5N1, have also 
been known to infect humans.[40, 41] Influenza B, conversely, is classified into distinct lineages, 
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specifically B/Yamagata and B/Victoria.[37] Both influenza A and B are then further categorized 
into clades and sub-clades.[37]  
Influenza B has exhibited far less genetic variation than influenza A, remaining relatively 
homogenous until the 1970s when antigenically distinct lineages began to diverge.[42, 43] A 
number of influenza A subtypes, however, have circulated since the virus was first isolated, with 
new subtypes frequently leading to severe epidemics, and even pandemics. Since the beginning 
of the 20th century the world has experienced four influenza pandemics (1918, 1957, 1968, and 
2009).[44] The 1918 and 2009 pandemics were caused by A/H1N1 strains while those in 1957 
and 1968 marked the emergence of H2N2 (no longer believed to be circulating), and H3N2 
respectively.[44] Influenza-associated pneumonia has been implicated as a substantial driver of 
mortality in these pandemics, but our understanding of the inter-pandemic burden and the 
importance of influenza’s interactions with bacteria remain limited.  
 Influenza has been associated with both primary viral pneumonia (caused directly by the 
virus itself) and secondary bacterial pneumonia (caused indirectly by facilitating bacterial 
colonization and/or infection.[45] Laboratory studies have identified likely mechanisms through 
which influenza may facilitate bacterial pneumonias, but the exact process remains uncertain.[45, 
46] Regardless, we would expect primary viral pneumonias to occur approximately concurrent 
with influenza infection, and secondary bacterial pneumonias to occur following some lag.[46-
48] Davis et al. explained the logic behind this assumption stating:  
“…we would expect to see a relatively long lag time between influenza infection and the 
presence of CAP [community acquired pneumonia] because of the time needed for the 
influenza to reduce the ability of the lungs to clear a bacterial infection...The bacterial 
 6 
agent would then have to proliferate within the host before the host began to show 
symptoms.”[46]  
This trend has been observed at a population level with studies showing cases of pneumonia tend 
to peak 1-3 weeks after influenza cases.[47, 49] However, such studies are inherently limited in 
the causal inferences that can be drawn from them. Particularly, we cannot be certain that these 
population-level correlations hold true at the individual-level (ecologic bias). A small number of 
studies have tried to assess this association at an individual-level, but have been limited by small 
sample size and seasonal confounding.[50, 51]  
While the temporal dynamics between influenza and severe illness remain uncertain, it is 
clear that influenza remains a substantial source of severe illness and death worldwide, 
particularly among young children.[8] A 2020 systematic review and modeling study reported 
that in 2018 there were an estimated 109.5 million (uncertainty range [UR]: 63.1-190.6 million) 
influenza episodes that occurred globally among children aged < 5 years. Of these, 
approximately 10% were classified as ALRI and 870,000 (UR: 543,000-1,415,000) were severe 
enough to require hospitalization.[52] The same study also estimated there were up to 34,800 
deaths (UR: 13,200-97,200) resulting from influenza-associated ALRI.[52] As with RSV, the 
majority (82%) of in-hospital deaths associated with influenza occurred in LMICs.[52] It’s 
notable that such a substantial burden persists despite having greater means of prevention and 
treatment than RSV.   
1.3.2 Treatment and Prevention 
Multiple antiviral medications against influenza have been developed since the virus was 
first isolated. The FDA approved amantadine as a prophylactic against H2N2 in 1966, and for 
use against other influenza A subtypes ten years later.[53] This was followed by Rimantadine, a 
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derivative of amantadine was approved for use in the US in 1993, and the first neuraminidase 
inhibitor, Oseltamivir (Tamiflu®), in 1999.[53] While the spread of influenza strains resistant to 
Oseltamivir has not yet become a substantial problem, it remains a concern.[53, 54] Past 
experience with resistance to amantadine and rimantadine underscores the importance of 
continuing to develop new therapeutics, particularly those which operate through different 
mechanisms. Fortunately, antiviral drugs are not the only means by which to combat influenza, 
as vaccination continues to be an integral component prevention and mitigation strategies. 
Vaccination has been the central tool in the effort to reduce seasonal influenza burden for 
decades. In fact, the first influenza vaccines were developed and licensed for use by the 1940s, 
the decade after influenza was first isolated.[55, 56] However, influenza vaccine effectiveness 
has varied widely over time. A recent meta-analysis showed that vaccine effectiveness varies by 
influenza type/subtype as well. Vaccine effectiveness was highest for influenza A H1N1pdm09 
at 61% (95% CI: 57, 65), followed by influenza B with 54% (95% CI: 46, 61), and A/H3N2 with 
33% (95% CI: 26, 39).[57] This is not to say that our current influenza vaccines are without 
value. Multiple studies have shown that influenza vaccination results in millions of fewer 
influenza illnesses and tens of thousands fewer hospitalizations.[58-60] Despite this, influenza is 
still estimated to be responsible for approximately 10% of respiratory hospitalizations globally 
among children aged <18 years.[8] This persistent burden highlights the importance of exploring 
the mechanisms involved with severe influenza illness. 
Antibiotics also play an important role in treating influenza-associated ALRIs like 
pneumonia as influenza may have facilitated the development of a bacterial infection that is 
actually causing the illness.[45, 46] However, with the growing challenge of antibiotic 
resistance, it is crucial that antibiotics only be used in those illnesses that are bacterial in nature. 
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Unfortunately, this is challenging even with advanced diagnostics[61], leading acute respiratory 
infections to become one of the largest sources of antibiotic misuse. A 2016 analysis of U.S. 
prescribing behavior in 2010-2011 reported that ARIs were responsible for 221 antibiotic 
prescriptions per 1000 population annually (95% CI: 198-245), but only 111 prescriptions per 
1000 were deemed appropriate.[62] Better understanding of the relationship between influenza 
and subsequent viral and bacterial pneumonias may lead to intervention strategies that decrease 
inappropriate use of antibiotics.  
1.3.3 Research Gaps 
While there are many important gaps in our understanding of influenza, the manner in 
which influenza and pneumonia are associated remains a particularly important challenge. 
Though pneumonia is frequently used as a measure of severe influenza, the research examining 
pneumonia etiology has substantial limitations. In 2011, the Pneumonia Etiology Research for 
Child Health (PERCH) study was started in an effort to update understanding of pneumonia 
etiology.[63] Knowledge to that point had come largely from studies conducted between the 
1970s and the 1990s, using data before the AIDS epidemic or the introduction of important 
vaccines—both of which altered populations’ susceptibility to pneumonia.[63, 64] A multi-site 
case-control study conducted at 9 sites in 7 countries, PERCH used more sophisticated molecular 
diagnostics to explore pneumonia etiology to a depth not previously possible. By the time of its 
completion in 2014, 4232 cases and 5325 controls had participated.[7] The scale of this 
undertaking is a striking indicator of the importance of understanding pneumonia etiology. Still, 
the challenges associated with such an effort are substantial.[65] Though the initial results were 
published in June 2019, the case-control design utilized in the study limits causal inference and 
any detailed assessment of the temporal dynamics between respiratory pathogens and subsequent 
 9 
pneumonia.[7] These questions can still only be effectively answered through large-scale, 
prospective cohort studies. 
1.4 Dissertation Aims 
1.4.1 Aim 1 - Assess and describe the burden of symptomatic RSV illness among 
Nicaraguan children aged < 2 years. 
In chapter two, I will discuss Aim 1 of my dissertation, focused on describing the burden 
of symptomatic RSV illness within a prospective, community-based study of Nicaraguan 
children aged < 2 years. Acute respiratory infections (ARI) are the most common communicable 
cause of death among Nicaraguan children, responsible for 15% of deaths in children under 
five.[6] However, the etiology of these infections remains poorly explored. With RSV estimated 
to be responsible for more than 1/5 of ALRI cases worldwide, it is important that the nature of 
RSV’s burden in Nicaragua be examined.[66] This analysis, provides the first in-depth look into 
the burden of RSV in Nicaragua, its seasonality, and the frequency of severe outcomes 
associated with it. 
1.4.2 Aim 2 - Explore whether influenza infection is temporally associated with 
pneumonia at a participant level among Nicaraguan children aged 0-14 years. 
In chapter three, I will discuss Aim 2 of my dissertation, exploring whether acute viral 
respiratory infection (specifically influenza) is associated with pneumonia at a participant level 
among Nicaraguan children aged 0-14 years. Influenza is considered a substantial contributor to 
the global burden of pneumonia—directly through viral pneumonia [61, 67], and indirectly 
through secondary bacterial pneumonia [46, 49], though as previously described, pneumonia 
etiology remains poorly understood. Multiple studies have suggested that secondary bacterial 
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pneumonia was a primary driver of mortality in influenza pandemics including that in 1918 [68, 
69], and more recently, 2009.[49, 70-72] However, it is unclear whether this association extends 
to inter-pandemic periods. By studying influenza and subsequent pneumonia among Nicaraguan 
children between 2011 and 2018, we aim to better understand the importance of influenza in 
driving pneumonia burden and identify temporal variation in pneumonia risk following 
influenza. 
1.4.3 Aim 3 – Characterize the temporal dynamics between influenza and clinical 
pneumonia before and after the introduction of the pneumococcal conjugate vaccine 
Bacterial pneumonia caused by pathogens like Streptococcus pneumoniae has been a 
considerable source of global morbidity and mortality.[73] Fortunately the introduction of 
pneumococcal conjugate vaccines (PCV) has led to major decreases in this burden.[74, 75] Since 
S. pneumoniae has been implicated as a key source of secondary bacterial pneumonias following 
influenza [50, 68], we might expect that the introduction of PCV would also lead to a reduction 
in the occurrence of influenza-associated pneumonias. However, this has been little studied in 
the literature. In chapter 4, I will discuss Aim 3 of my dissertation, where we characterize the 
risk and temporal dynamics of pneumonia following influenza in two cohorts of Nicaraguan 
children—one prior to the introduction of PCV to Nicaragua, and the other after its introduction 
and near universal adoption. Comparing the relationship between influenza and pneumonia in 
these two groups will provide important insights into the interaction of influenza with bacterial 
pathogens which contribute to severe illness.  
Respiratory Syncytial Virus (RSV) and influenza are two of the most substantial 
contributors to the burden of ALRI, responsible for an estimated 22% and 13% respectively of 
all cases in children, and more than 200,000 deaths in a given year.[1, 76, 77] My dissertation, as 
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aims explore several important questions that remain regarding the burden of RSV, and the 
temporal dynamics between influenza and pneumonia in Nicaragua.
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Chapter 2 Assessing the Incidence of Symptomatic Respiratory Syncytial Virus (RSV) 
Illness Within a Prospective Birth Cohort in Managua, Nicaragua 
 
 
2.1 Author Summary 
 We found a substantial burden of RSV among Nicaraguan children under 2 years. 
Around 1/3 of deaths from medical causes were RSV-associated, suggesting it’s an important 
driver of infant mortality in highly vaccinated populations with little HIV or malaria. 
 
2.2 Abstract 
 Respiratory syncytial virus (RSV) causes substantial morbidity and mortality among 
children worldwide, commonly through acute lower respiratory tract infections (ALRI). To 
assess the incidence of symptomatic RSV illness among young children, we conducted a 
prospective birth cohort study following children from 0-2 years of age in Managua, Nicaragua. 
 Children meeting the testing criteria (fever, history of fever, or severe respiratory 
symptoms [apnea, stridor, nasal flaring, wheezing, chest indrawing, and/or central cyanosis]), 
were tested for RSV infection using real-time reverse transcriptase-polymerase chain reaction. 
Acute lower respiratory infection was defined as diagnosis of pneumonia, bronchiolitis, 
bronchitis, or bronchial hyper-reactivity. Incidence was calculated, and 95% confidence intervals 
estimated using a Poisson distribution. 
 A total of 833 children participated in the cohort, 289 (34.7%) had at least one episode of 
laboratory-confirmed RSV, and 156 (18.7%) of RSV-associated ALRI (RSV-ALRI). The 
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incidence of symptomatic RSV was 248.1 cases per 1000 person-years (95% confidence interval 
[CI]: 223.2, 275.7). While infants aged 6-11 months had the highest incidence of symptomatic 
RSV (361.3/1000 person-years, 95% CI: 304.4, 428.8), infants <3 months had the highest 
incidence of severe RSV (RSV-associated hospitalizations and/or severe ALRI). RSV was also 
associated with 25.0-37.5% of deaths from medical causes (n=8). 
 A substantial burden of RSV exists among children aged <2 years in Nicaraguan 
communities. RSV was also a leading cause of infant mortality among study participants. 
Development and implementation of effective RSV prevention and treatment measures represent 
an opportunity to substantially reduce severe illness and death among children worldwide. 
 
2.3 Introduction 
 Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory tract 
infections (ALRI) like pneumonia and bronchiolitis, particularly among children.[66] In 2015, 
there were an estimated 33.1 million cases of RSV-associated ALRI (RSV-ALRI) worldwide, of 
which 3.2 million required hospitalization.[2] This burden is especially pronounced among 
young children, with an estimated 1.4 million RSV-ALRI hospitalizations and 27,300 in-hospital 
deaths among infants aged < 6 months.[2]  
 Significant disparities exist in the distribution of RSV-associated mortality, with an 
estimated 99% of in-hospital deaths occurring in low- and middle-income countries (LMICs).[3] 
In Nicaragua, severe acute respiratory infections (SARIs) remain the leading communicable 
cause of death among children aged <5 years.[6] While increasing attention has been given in 
recent years to improving our understanding of the global burden of RSV, substantial knowledge 
gaps remain in LMICs. Many studies have used hospital-based populations to study RSV burden 
[28-34], but community-based studies are less common.[13, 14, 67, 78, 79]  
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 Clinically, RSV infection often presents with respiratory symptoms like cough, 
rhinorrhea, and difficulty breathing. As many as 97% of children are infected with RSV by age 
2.[12] RSV has also been associated with the development of severe illness and is considered the 
most common viral cause of pneumonia among children aged <5 years.[80] In Nicaragua, the 
respiratory illness season can last from June through February. While the seasonality of influenza 
in Nicaragua has been documented [81], the seasonality of RSV and other respiratory viruses is 
not well-defined. 
 RSV has long been a target for vaccine development because of its ubiquity and potential 
for causing severe illness. An overview of RSV vaccines and monoclonal antibodies in 
development reported 21 candidates in clinical trials.[25] Addressing knowledge gaps about the 
burden of RSV is crucial to the investment case for these interventions, and their successful 
future implementation. This study aims to assess the incidence of RSV among young children in 
Nicaragua, a lower-middle income tropical country in Central America.[82] We used the 
Nicaraguan Influenza Birth Cohort Study [83], originally designed to examine the incidence of 




2.4.1 Ethics statement 
 This study was conducted as a collaboration between the Sustainable Sciences Institute, 
the Nicaraguan Ministry of Health, the University of California, Berkeley (UCB), the University 
of Michigan, and the US Centers for Disease Control and Prevention (CDC). The study was 
approved by the Institutional Review Boards (IRBs) of the Nicaraguan Ministry of Health, 
 15 
University of Michigan, and UCB. The CDC’s IRB relied on the UCB IRB for approval. Written 
informed consent was obtained from a parent/guardian of all participants. 
2.5 Study population 
 A detailed description of this study has been previously published.[83] The Nicaraguan 
Influenza Birth Cohort Study was a prospective cohort study conducted year-round from 2011-
2016 in the catchment area of the Health Center Sócrates Flores Vivas (HCSFV) in Managua, 
Nicaragua. Continuous enrollment of newborns was conducted between September 8, 2011, and 
September 5, 2014 (Figure 2.1). Eligible subjects were identified when brought to the HCSFV 
for their first well-baby visit, or by home visits. Those who met the enrollment criteria, and for 
whom informed consent was received, were enrolled into the study. To be included, (1) infants 
had to be ≤ 4 weeks of age at enrollment, (2) live in the HCSFV catchment area, (3) infants’ 
guardians had to plan to live in the area during the following 2 years, and (4) guardians had to be 
willing to attend HCSFV for all the infant’s medical visits. Infants who required continued 
hospitalization directly after birth for ≥4 weeks were not eligible. Enrolled participants remained 
in the study until their 2nd birthday, they were withdrawn, or were lost to follow-up. 
2.5.1 Data  
 Baseline information about demographics, risk factors, and socioeconomic status were 
collected through surveys conducted by study staff at enrollment and yearly in March/April. 
Daily symptom diaries were completed by parents and were collected by study staff during 
weekly home visits. Respiratory samples were collected from infants who met the testing 
definition by presenting with (1) influenza-like illness (ILI) — fever (temperature ≥37.8°C) or  
history of fever and rhinorrhea and/or cough [84]; (2) fever or history of fever without  defined 
focus; (3) severe respiratory symptoms (i.e., apnea, stridor, nasal flaring, wheezing, chest 
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indrawing, and/or central cyanosis) as judged by a study physician, regardless of the presence of 
fever/history of fever; or (4) those hospitalized with respiratory symptoms (previously listed) or 
sepsis.[83]   
2.5.2 Sample collection and RSV testing 
 Oropharyngeal specimens collected with un-flocculated polyester tipped plastic swabs 
(Fisher Scientific, catalog number: 23-400-111) were obtained from infants aged <6 months who 
met the testing definition, while combined nasal and oropharyngeal swabs were collected from 
infants aged ≥6 months. Laboratory testing for RSV was conducted by the National Virology 
Laboratory at the National Center for Diagnosis and Reference (CNDR) of the Nicaraguan 
Ministry of Health. The CNDR has demonstrated proficiency in RSV testing through CDC-
QCMD (Quality Control for Molecular Diagnostics) External Quality Assessment.[85] RNA was 
extracted (QIAamp Viral RNA Mini Kit, Qiagen) and tested by real-time RT-PCR for RSV 
using CDC protocols.[86]   
2.5.3 Clinical definitions 
 Clinical care was provided to all study participants at the HCSFV by study personnel, and 
data were collected for each encounter, regardless of the reason for the visit. Laboratory-
confirmed cases of RSV were classified as symptomatic RSV illness. Samples positive for RSV 
occurring ≥14 days from symptom onset for a previous RSV illness were considered new illness 
episodes. Symptomatic RSV illness was further classified as ALRI (RSV-ALRI) if study 
physicians diagnosed acute illness affecting the lower respiratory tract (i.e., pneumonia, 
bronchiolitis, bronchitis, or bronchial hyper-reactivity). Pneumonia diagnosis was made by study 
physicians according to the Integrated Management of Childhood Illness (IMCI) guidelines.[87] 
Severe ALRI was used instead of severe pneumonia as done by Shi et al.[2] Cases of ALRI, 
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severe ALRI, and hospitalization occurring within 14 days of symptom onset of a laboratory-
confirmed RSV illness episode were considered associated with RSV.   
2.5.4 Statistical analysis 
 Person-time was calculated as the number of weeks between participant enrollment and 
their exit from the study (at their 2nd birthday, or when withdrawn or lost to follow-up). Infants 
were not considered to be at risk for the 14 days following symptom onset for an RSV illness 
episode and were thus excluded from contributing person-time—except for measures intended to 
assess severe RSV (RSV-ALRI, RSV-severe ALRI, and RSV-hospitalization). A Poisson 
distribution was used to calculate 95% confidence intervals for incidence rates. Statistical 
analyses were conducted using SAS version 9.4 (SAS Institute Inc.). Figures were created using 
R version 3.4.4 (R Foundation for Statistical Computing). 
 
2.6 Results 
 Between the start of enrollment in September 2011 and study conclusion in September 
2016, 833 infants were enrolled into the cohort and included in this analysis. The mean follow-
up time for participants was 1.7 years (19.9 months) (Table 2.1). A total of 9 (1.1%) infants died 
during the study, with 8 (88.9%) deaths associated with medical illnesses and 1 (11.1%) resulting 
from an unknown cause. Over 75% of infants completed the study (n=629), while 23.4% 
(n=195) were withdrawn or were lost to follow-up before study completion. The most common 
reason infants were withdrawn from the study or were lost to follow-up (60.3%, n=123) was 
because the child moved away from the study area. We did not observe any significant 
differences between the demographics of those who completed the study and those who did not 
(Table 2.2).   
 18 
 There were a total of 17,209 visits to the study clinic; of these, 15,508 (90.1%) were for 
acute illness. The median number of clinic visits per participant was 18 (IQR: 20), and 814 
(97.7%) of participants had at least 1 visit.  
2.6.1 Incidence of symptomatic RSV illness 
 Participants contributed a total of 1,417.3 person-years and experienced 344 laboratory-
confirmed episodes of symptomatic RSV illness, 11 (3.2%) of which were co-infected with 
influenza A. We did not observe differential illness severity among those co-infected. Of the 833 
infants, 289 (34.7%) had at least 1 documented episode of symptomatic RSV illness. Of these, 
50 (17.3%) infants had recurrent (≥2) episodes of symptomatic RSV illness, and 5 (1.7%) 
experienced 3 episodes of symptomatic RSV illness. The crude incidence of symptomatic RSV 
illness was 248.1 cases per 1000 person-years (95% CI: 223.2, 275.7) (Table 2.3). Incidence of 
symptomatic RSV illness increased steadily with age, peaking among infants aged 6-11 months 
at 361.3 cases per 1000 person-years (95% CI: 304.4, 428.8), before falling to 249.2 per 1000 
person-years (95% CI: 214.0, 290.1) among those aged 12-23 months (Table 2.3 and Figure 2.2). 
One-hundred and seventy-six (51.2%) symptomatic RSV illnesses did not present with 
nurse/physician measured fever (≥38°C); including measured fever in the symptomatic RSV 
illness case definition decreased rates by 37-66% (Table 2.4). RSV epidemics started as early as 
May, and as late as September, lasting an average of 6.9 months (range: 4-7 months) (Figure 
2.3).  
2.6.2 Incidence of RSV-associated ALRI and severe ALRI 
 Of the 344 laboratory-confirmed cases of symptomatic RSV illness identified in the 
study, 170 (49.4%) were classified as ALRI (Table 2.5), resulting in an overall incidence rate for 
RSV-ALRI of 119.9 cases per 1000 person-years (95% CI: 103.2, 139.4). Incidence of RSV-
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ALRI followed a similar trend across age groups as that of symptomatic RSV illness with 
incidence increasing with age until peaking among participants aged 6-11, with 181.8 cases per 
1000 person-years (95% CI: 143.1, 231.0). While children aged <3 months had the lowest 
overall RSV illness rates, they had the highest rate of RSV-severe ALRI (Figure 2.4, Table 
2.5)—though the differences between age groups were not statistically significant. 
 Among the 170 cases of RSV-ALRI, 21 (12.4%) had severe illnesses (Table 2.5), with an 
incidence of RSV-severe ALRI of 14.8 cases per 1000 person-years (95% CI: 9.7, 22.7). 
Participants aged <3 months had the highest incidence of RSV-severe ALRI, with 31.4 cases per 
1000 person-years (95% CI: 13.1, 75.5). Except for a sharp decline among those 3-5 months of 
age, the incidence of RSV-severe ALRI decreased as age increased (Figure 2.4). While episodes 
of symptomatic RSV illness were less frequent among the youngest participants—aged <3 
months— (Table 2.3 and Table 2.5), those that did occur were more likely to be severe. Eighty 
percent of children aged <3 months with symptomatic RSV illness had RSV-ALRI (vs. 56.8% 
among 3-5 months, 51.2% among 6-11 months, and 44.6% among 12-23 months, chi-square 
p=0.1);  additionally, 50% of  children aged <3 months with symptomatic RSV illness had  RSV-
severe ALRI (vs. 2.7% among 3-5 months, 6.1% among 6-11 months, and 4.2% among 12-23 
months, chi-square p<0.0001).  
2.6.3 Incidence of RSV-associated hospitalizations 
 The incidence of RSV-associated hospitalizations was 22.6 cases per 1000 person-years 
(95% CI: 16.0, 31.9). Aside from a precipitous drop among those aged 3-5 months, incidence of 
RSV-associated hospitalization steadily decreased as age increased, with infants aged <3 months 
having the highest incidence (37.7 cases per 1000 person-years, 95% CI: 16.9–83.9) (Table 2.6).  
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2.6.4 RSV-associated deaths 
 Of the 8 infants who died from medical causes during the study, 3 (37.5%) died of severe 
pneumonia (all in-hospital) and were RT-PCR-positive for RSV in the weeks preceding their 
death. Two (25.0%) of these deaths occurred within 2 weeks (1 and 14 days) of symptom onset; 
the infant who died 1 day after testing positive for RSV was 4 months old, while the infant who 
died 14 days after symptom onset was aged 10 months. One additional infant (aged 11 months) 
died of severe pneumonia 46 days after symptom onset. The RSV-associated mortality rate 
among infants ranged from 2.8 deaths per 1000 person-years (95% CI: 0.7, 11.1) using a 14 day 
risk period to 4.2 per 1000 person-years (95% CI: 1.3, 12.9) when considering the deaths that 
occurred up to 46 days after laboratory-confirmation with RSV. 
 
2.7 Discussion 
 Using data from a community-based prospective birth cohort study, we found a high 
incidence of symptomatic RSV illness in Nicaragua in children aged <2 years. Infants aged <3 
months had the highest rates of severe RSV infection outcomes, including severe ALRI and 
hospitalization. In our birth cohort, laboratory-confirmed RSV illness was associated with one 
third of deaths. In this population many common contributors to infant mortality in LMICs are 
missing as >98% children received WHO recommended immunizations [88], the prevalence of 
HIV is low [89], and malaria is absent, suggesting RSV is a significant contributor to infant 
mortality. This finding has important implications for a number of countries that have full 
coverage under the Expanded Program on Immunization (EPI), but still struggle to lower infant 
mortality. 
 Our findings are consistent with published estimates from other parts of the world.[13, 
14, 90] In a review of the 2015 global burden of RSV-ALRI, Shi et al. reported incidence rates 
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ranging from 26.6–343.8 per 1000 person-years among children aged 0–5 months, 18.0–338.1 
among those aged 6-11 months, and 21.8–304.3 among those aged 12-23 months.[2] One study, 
conducted in the Peruvian highlands, was responsible for the highest estimates in all age 
groups—reporting rates approximately double those of the next highest estimates (Table 2.7).[2, 
91] Our RSV-associated ALRI estimates were similar to the majority of studies referenced by 
Shi et al. (i.e., 67, 160, and 93 per 1000 person-years among children aged 0-5, 6-11, and 12-23 
months, respectively). We did observe rates of symptomatic RSV and ALRI that peaked later 
(among infants 6-11 months) than other studies.  It is possible that our age-specific estimates of 
symptomatic RSV are biased from the inclusion of reported/measured fever as RSV illness 
presenting with fever increases with age. However, a study in Guatemala [35] showed a similar 
pattern suggesting that regional variations might impact the age distribution of RSV incidence. 
 There are limited published data about the incidence of RSV in community settings in 
low- and middle-income countries (LMICs), especially in Central America.[2] Shi et al. 
compiled data from 329 studies, of which only 14 (4%) were community-based with active case-
ascertainment.[2] Of these 14, only one was from Central America (Guatemala).[35] The 
Guatemalan study reported an incidence of RSV pneumonia among children aged ≤18 months of 
143.6 per 1000 person years (116.2, 177.3).[35] While the Guatemala estimate was higher than 
the estimate in our study (70.6 cases per 1000 person-years (95% CI: 58.0, 85.8)—Table 2.7), 
this is likely because in the Guatemalan study RSV-ALRI cases were identified only from 
children with physician diagnosed pneumonia, not the overall study population.   
 Identifying and quantifying RSV-associated mortality is challenging, and the most 
appropriate time period to use in classifying deaths associated with RSV remains a subject of 
debate.[92] RSV-associated mortality might peak weeks after the original RSV infection and 
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perhaps be associated with secondary bacterial infection.[93-95] A recent examination of RSV 
mortality in Minnesota included deaths that occurred within an 8-week period of laboratory 
confirmation.[96] Moreover, quantification of RSV-associated mortality in community-based 
studies is limited by the fact that only a relatively small number of deaths are expected. 
However, in our study, out of 8 deaths from medical causes, 2 deaths seemed clearly associated 
with RSV because they occurred within two weeks of the onset of laboratory-confirmed RSV 
illness, and one could argue that a third death (approximately 6 weeks following RSV 
laboratory-confirmation) was also associated with RSV illness. Thus, 25% or 37.5% of deaths 
from medical causes were associated with RSV. 
This study has a number of strengths. This community-based study provides insight about 
the largely undocumented burden of RSV in communities in LMICs where a substantial 
proportion of the population might not seek hospital care for severe illness. The study enrolled 
children from birth and actively monitored them each week throughout the year for respiratory 
illnesses. As a prospective, longitudinal cohort study, we were able to calculate incidence and 
examine four seasonal RSV epidemics. Finally, by including neonates, we document RSV rates 
in a younger age group than much of the existing literature.  
Multiple hospital-based studies have demonstrated that the inclusion of fever (measured--
≥38°C--or reported) in case definitions results in an underestimate of RSV cases—particularly 
among children aged < 1 year.[97-99] Studies using data from cohorts initially designed to study 
influenza (like this one) are susceptible to such underestimates as case definitions like influenza-
like illness and severe acute respiratory illness reflect influenza’s more frequent presentation 
with fever. While we were unable to make the direct comparisons across a variety of case 
definitions like Saha [98], Nyawanda [97], and Rha et al. [99], we did conduct sensitivity 
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analyses examining the effect of including nurse/physician measured fever (≥38°C) on RSV 
rates. Had measured fever been included as a required criteria for sampling and/or testing, our 
estimated incidence rates would have been 30-70% lower depending on participants’ age. Such 
findings suggest the value of developing RSV-specific case definitions—like those pursued 
through the WHO’s Global RSV Surveillance Pilot.[100] While our testing definition likely 
missed some cases of symptomatic RSV infection—particularly among those aged < 1 year—the 
majority of any missed cases were most likely among those with less severe illness. The 
inclusion of any severe respiratory symptoms (regardless of fever/history of fever) in this study’s 
testing criteria suggests that our assessments of more severe manifestations of RSV are good 
approximations of the true severe RSV burden in our study community. Future studies in this 
population are underway to examine the specific risk and prognostic factors contributing to this 
burden. 
This study demonstrates that a substantial burden of RSV exists among children aged <2 
years in Nicaragua. This coupled with the high proportion of infant deaths associated with RSV 
illness underscores the importance of RSV in such communities. Such findings demonstrate the 
merit of exploring the cost-benefit of current interventions, and continued support for those being 
developed for pregnant women and young children, to prevent RSV illness among this high-risk 
group. Development and implementation of effective RSV prevention represents a prime 






Figure 2.1: Plot of Categorical Age Distribution Over the Course of the Study 
Count of enrolled participants by age category across study duration.  
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Table 2.1: Characteristics of Study Participants 
Characteristic  Total No. = 833a 
Age at enrollment 0-2 weeks 581 (69.8) 
 3-4 weeks 249 (29.9) 
 5-6 weeks 3 (0.4) 
Male  415 (49.8) 
Mean follow-up time, person-years    1.7 (0.6b) 
Smoking in household  249 (29.9) 
Mean number of persons in household  8.7 (4.4b) 
Mothers with secondary or tertiary education  
(No. = 830) 
 677 (81.3) 
Fathers with secondary or tertiary education  
(No. = 810) 
 644 (77.3)  
Water tap location Outside 291 (35.0) 
 Inside 541 (65.0) 
Dirt floor Yes 94 (11.3) 






Table 2.2: Characteristics of Study Participants by Completion Status 





 No. 833 629 204  
Age at enrollment 0-2 weeks 581 (69.8) 442 (70.3) 139 (68.1) 0.209 
 3-4 weeks 249 (29.9) 186 (29.6) 63 (30.9)  
 5-6 weeks 3 (0.4) 1 (0.2) 2 (1.0)  
Sex Male 415 (49.8) 311 (49.4) 104 (51.0) 0.747 
 Female 418 (50.2) 318 (50.6) 100 (49.0)  
Mean person-years 
contributed 
 1.7 (0.6a) 1.9 (0.05a) 1.2 (0.5a) <0.001 
Smoking in household Yes 249 (70.1) 188 (29.9) 61 (29.9) 0.997 
 No 584 (29.9) 441 (70.1) 143 (70.1)  
Mean number in household 8.7 (4.4a) 8.7 (4.4a) 8.85 (4.2a) 0.337 
Mothers with secondary or  
tertiary education 





Fathers with secondary or  
tertiary education 













 Characteristic RSV 
cases 
Person-years Incidence rate (95% CIa) 
per 1000 person-years 
All participants 344 1386.8 248.1 (223.2, 275.7) 
Age  <3 months 10 149.6 66.8 (36.0, 124.2) 
 3-5 months 37 208.2 177.7 (128.8, 245.3) 
 6-11 months 131 362.7 361.2 (304.3, 428.6) 
 12-23 months  166 666.3 249.2 (214.0, 290.1) 
Sex Male 176 692.9 254.0 (219.1, 294.5) 
 Female 168 693.9 242.1 (208.2, 281.7) 
aConfidence intervals calculated using a Poisson distribution. 
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Figure 2.2: Incidence of Symptomatic RSV Illness Episodes by Age 
The black line reflects the incidence rate of symptomatic RSV illness by week of age, while the 








 Characteristic RSV 
cases 
Person-years Incidence rate (95% CIa)  
per 1000 person-years 
% differenceb 
All participants 168 1386.8 121.2 (104.2, 140.9) 51.2% lower 
Age  <3 
months 
5 149.6 33.4 (13.9, 80.3) 50.0% lower 
 3-5 12 208.2 57.6 (232.7, 101.5) 70.3% lower 
 6-11 
months 
46 362.7 126.8 (95.0, 169.3) 64.1% lower 
 12-23 
months  
105 666.3 157.6 (130.2, 190.8) 36.8% lower 
Sex Male 87 692.9 125.6 (101.8, 154.9) 50.1% lower 
 Female 81 693.9 116.7 (93.9, 145.1) 51.8% lower 
aConfidence intervals calculated using a Poisson distribution. 
bWhen compared to incidence rates calculated from testing criteria using fever or history of fever 
(Table 2).  
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Figure 2.3: Incidence of Symptomatic RSV Illness by Study Week 
The black line reflects the incidence rate of symptomatic RSV illness by week of study, while 
the red line shows a Loess smoothing function applied to the data to illustrate the seasonal trend 
of RSV transmission. Data were truncated at the beginning and end of the study when the total 
number of participants in the study was below 100. 
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Incidence rate   





(95% CI)  
All participants 1417.4 170 119.9 (103.2, 139.4) 21 14.8 (9.7, 22.7) 
Age <3 months 159.2 8 50.3 (25.1, 100.5) 5 31.4 (13.1, 75.5) 
 3-5 months 210.0 21 100.0 (65.2, 153.4) 1 4.8 (0.7, 33.8) 
 6-11 months 368.6 67 181.8 (143.1, 231.0) 8 21.7 (10.9, 43.4) 
 12-23 
months  
679.7 74 108.9 (86.7, 136.7) 7 10.3 (4.9, 21.6) 
Sex Male 708.3 96 135.6 (111.0, 165.6) 12 16.9 (9.6, 29.8) 






Figure 2.4: Incidence of RSV-associated ALRI and RSV-associated Severe ALRI by Age 
Plot of incidence rates of RSV-associated acute lower respiratory tract infection (ALRI) and 
RSV-associated severe ALRI by age category. Lines around point estimates represent 95% 
confidence intervals estimated using a Poisson distribution. 
  
 33 
Table 2.6: Incidence of RSV-associated Hospitalization and RSV-associated Pneumonia by Age 
and Sex 












All participants 1417.4 32 22.6 (16.0, 
31.9) 
100 70.6 (58.0, 
85.8) 
Age <3 months 159.2 6 37.7 (16.9, 
83.9) 









368.6 12 32.6 (18.5, 
57.3) 




679.7 13 19.1 (11.1, 
32.9) 
43 63.3 (46.9, 
85.3) 
Sex Male 708.3 18 25.4 (16.0, 
40.3) 
55 77.7 (59.6, 
101.2) 
 Female 709.1 14 19.7 (11.7, 
33.3) 
45 63.5 (47.4, 
85.0) 




Table 2.7: Comparison of Incidence of RSV-ALRI Across Studies 
Location/ 
reference 
Incidence rate of RSV-ALRI  
per 1000 person-years (95% 
CI) 
Minimum criteria for 
sample 
collection/testing 












67  160  93 Fever (≥37.8°C), 




cohort study of 
children 0-2 years, 
enrolled from home or 
during well baby visits 
Peru[91]  343.8 338.1 304.3 Reported fever or 
cough in last 7 days 
Prospective cohort study 
including children aged 




147.0 63.0 71.0 Difficulty breathing, 
rhinorrhea and/or 
nasal congestion, or 
cough in last 7 days 
Prospective birth cohort 
over 4 calendar years, 
recruited from maternity 





150.0 110.0 120.0 Fever (≥38°C), 
difficulty breathing, 
cough, or rhinorrhea 
Prospective birth cohort 
of children 0-2 years, 




60.2 18.0 52.0 Cough or difficulty 
breathing 
Prospective birth cohort 
of children 0-3 years, 
recruited from 2 towns 
following identification 





107.7 172.4 124.5 Children diagnosed 
with pneumonia 
Randomized control 
trial of children ≤18 
months comparing 
homes with traditional 
or intervention cook 
stove 
Table adapted from review paper by Shi et al.[2] 
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Chapter 3 Individual-level Association of Influenza Infection With Subsequent 
Pneumonia: A Case-control and Prospective Cohort Study 
 
3.1 Author summary 
 We observed children with symptomatic influenza had substantially greater odds of 
developing pneumonia in the subsequent 30 days when compared to children without influenza. 
This elevated risk of pneumonia was also not consistent over this period, but was higher in the 
first and third weeks following influenza infection. These distinct periods of elevated risk 
suggest the existence of two etiologic pathways between influenza and pneumonia. 
3.2 Abstract 
Pneumonia is a leading cause of mortality worldwide. Influenza may result in primary 
pneumonia or be associated with secondary bacterial pneumonia. While the association with 
secondary pneumonia has been established ecologically, individual-level evidence remains 
sparse and the risk period for pneumonia following influenza poorly defined. 
We conducted a matched case-control study and a prospective cohort study among 
Nicaraguan children aged 0-14 years from 2011-2018. Physicians diagnosed pneumonia cases 
based on Integrated Management for Childhood Illness (IMCI) guidelines. Cases were matched 
with up to 4 controls on age (months) and study week. We fit conditional logistic regression 
models to assess the association between influenza subtype and subsequent pneumonia 
development, and a Bayesian non-linear survival model to estimate pneumonia hazard following 
influenza.  
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Participants with influenza had greater risk of developing pneumonia in the 30 days 
following onset compared to those without influenza (matched odds ratio [mOR]: 2.7, 95% CI: 
1.9, 3.9). Odds of developing pneumonia were highest for participants following 
A(H1N1)pdm09 illness (mOR: 3.7, 95% CI: 2.0, 6.9), followed by influenza B, and A(H3N2). 
Participants’ odds of pneumonia following influenza were not constant, showing distinct peaks 
0-6 days (mOR: 8.3, 95% CI: 4.8, 14.5) and 14-20 (mOR: 2.5, 95% CI: 1.1, 5.5) days post 
influenza infection.  
Influenza is a significant driver of both primary and secondary pneumonia among 
children. Distinct periods of elevated pneumonia risk in the 30 days following influenza supports 
multiple etiological pathways. 
 
3.3 Introduction 
 Despite progress in reducing morbidity and mortality, the global burden of pneumonia 
remains substantial, particularly among children in low- and middle-income countries 
(LMICs).[101] Influenza is an important contributor to pneumonia burden.[77] This may occur 
directly, as primary viral pneumonia[61], or indirectly through secondary bacterial 
pneumonia.[70] Seasonal influenza peaks coincide with, or are followed by, peaks of pneumonia, 
suggesting population-level association.[49, 102] Additionally, investigations of the 1918 and 
2009 influenza pandemics, make the case for secondary bacterial infections being drivers of 
mortality during influenza pandemics.[68, 70, 103-106] Laboratory studies have established 
plausible biological mechanisms through which influenza infection may lead to increased 
susceptibility to secondary bacterial pneumonia.[45, 107, 108]  However, substantial gaps in the 
literature remain that can only be addressed through large participant-level epidemiologic 
studies.[109, 110]  
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 Previous large-scale studies focused on individuals hospitalized for pneumonia. Though 
community comparisons strengthen some studies’ findings, respiratory samples were often 
collected concurrently with pneumonia diagnosis (cross-sectional), limiting causal inference. 
Studies which addressed the limitations of cross-sectional analysis faced different challenges, 
specifically small sample size[50] and seasonal confounding.[51]  
 We used a nested, matched case-control study and Bayesian time-to-event modeling to 
explore the risk of developing pneumonia following symptomatic influenza infection in a 
prospective cohort of Nicaraguan children aged 0-14. 
 
3.4 Methods 
3.4.1 Ethics statement 
 The study was approved by the Institutional Review Boards of the Nicaraguan Ministry 
of Health, University of Michigan, and University of California, Berkeley. Written informed 
consent was obtained from a parent/guardian of all participants. Verbal assent was obtained from 
children aged ≥6 years. 
3.4.2 Study population and sample collection 
 Study participants were from two prospective cohorts of Nicaraguan children, the 
Nicaraguan Influenza Birth Cohort and the Nicaraguan Pediatric Influenza Cohort. Participants 
were pooled as they were enrolled from the same population and shared the same data collection 
methods. The resulting cohort included children aged 0-14 years who participated in the study 
between 2011 and 2018. The methods employed in these studies have been described in detail 
previously.[111, 112] Briefly, healthy children were enrolled when brought to Health Center 
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Sócrates Flores Vivas (HCSFV), or were recruited through home visits. A detailed clinical 
history and sociodemographic survey were collected on enrollment and yearly thereafter. 
Nicaragua introduced the pneumococcal vaccine (PCV13) in 2010 with a three-dose schedule (2, 
4 and 6 months) and a catch-up dose for children aged 12-24 months.  By the end of 2012, nearly 
100% of infants were appropriately vaccinated for their age.[75]  
 Nasal and oropharyngeal swabs were collected from all children meeting the testing 
definition. Study nurses and physicians are available at HCSFV 24 h/day, 365 days/year, and 
parents agreed to bring their child to HCSFV at the first sign of fever. The criteria for sample 
collection and testing was illness onset within 4 days, fever or reported fever, and rhinorrhea 
and/or cough for children aged ≥ 2 years, or fever or reported fever for children aged < 2 
years.[111] Respiratory samples were also collected/tested for influenza for any child presenting 
with clinical pneumonia or severe respiratory illness (i.e. requiring transfer to hospital).  
3.4.3 Laboratory methods 
 RNA was extracted from swabs (QIAamp Viral RNA Mini Kit, Qiagen) and tested for 
influenza A and B using validated CDC RT-PCR protocols.[86] Influenza A positive samples 
were subtyped according to CDC protocols.[111] Samples were not tested for bacterial 
pathogens and influenza B lineage was not considered in this analysis. 
3.4.4 Data collection and case definitions 
 Yearly surveys assessing household and participant-level risk factors were completed in 
March/April, before the typical start of seasonal influenza transmission in June.[111] With each 
visit to the study health center, a comprehensive medical consult form was completed. These 
data were also collected at follow-up visits, which were scheduled until the participant’s illness 
clears, with frequency of visits depending on severity.  
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 Study physicians identified cases of clinical pneumonia among those presenting to the 
clinic using age-specific guidelines for rapid breathing from the Nicaraguan Ministry of Health 
based on the Integrated Management of Childhood Illness (IMCI) (Table 3.1).[113] Parents 
reported the onset date of symptoms which was used as the start of the influenza-episode in all 
subsequent analyses. Diagnosis date was used to define pneumonia onset. Pneumonia episodes 
occurring within 0-6 days of influenza illness onset were considered cases of likely primary viral 
pneumonia, while those occurring ≥7 days after influenza onset were considered likely 
secondary bacterial pneumonias.[50]  
3.4.5 Statistical analysis 
 Two study designs were employed: a nested, matched case-control study, and a 
prospective cohort study. Conditional logistic regression models were fit using the survival 
package, survival models were fit with the brms package for Bayesian regression modeling with 
Stan, and figures were generated with ggplot2 and the tidybayes packages for R 3.6.1.[114-117] 
 Matched case-control 
 Pneumonia cases were matched to up to 4 controls on age (months) and study week 
ensuring the appropriate risk set was used when assigning controls. Controls were selected from 
the cohort at large after excluding those with a pneumonia diagnosis in the previous 45 days 
(Figure 3.1). Children were able to serve as a case (if distinct episode) or control multiple times 
if they met the previously described criteria.  
To explore the relationship between influenza subtype and risk of pneumonia in the 30 
days following onset, a conditional logistic regression model was fit (Model 1) with categorical 
variable (𝑠𝑖𝑘) indicating no influenza, H3N2, H1N1pdm09, or influenza B for case 𝑖 in pair k. To 
assess the risk period for pneumonia following symptomatic influenza infection, a separate 
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conditional logistic regression model was fit (Model 2), with categorical variable (𝑤𝑖𝑘) assessing 
the risk of pneumonia in 0-6, 7-13, 14-20, and 21-30 days following influenza infection. Those 
without influenza in the 30 days prior to the case’s pneumonia diagnosis were the reference 
group. 
Model 1: 
𝑙𝑜𝑔𝑖𝑡(𝑦𝑖𝑘) =  𝛼𝑘 + 𝛽1𝑠𝑒𝑥𝑖𝑘 + 𝛽2 𝑠𝑖𝑘 
 
Model 2: 
𝑙𝑜𝑔𝑖𝑡(𝑦𝑖𝑘) =  𝛼𝑘 + 𝛽1𝑠𝑒𝑥𝑖𝑘 + 𝛽2 𝑤𝑖𝑘 
Bayesian survival model 
 To estimate the daily rate of pneumonia during the 30 days following influenza onset in 
the entire cohort, we used a discrete time survival model, in which the outcome 𝑦𝑖𝑡= 1 denotes 
that individual i was diagnosed with pneumonia on day t of the study period, and 𝑦𝑖𝑡 = 0 
indicates that the individual was not. We fit a model with two penalized spline terms: 1) for the 
month of study (1:95), denoted as 𝜆0(𝑡), where 𝜆0(𝑡) is a function mapping days to the baseline 
log-hazard of pneumonia for the month containing day t. To represent the log-hazard ratio of 
pneumonia risk on each day post-influenza, we defined a second smoothed term, 𝑓(𝑡 − 𝜁𝑖 , 𝑠𝑖), 
where 𝜁𝑖is the day of influenza onset for individual i, and 𝑠𝑖 indicates the infecting influenza 
subtype (H3N2, H1N1pdm09, or B). This allowed for the modeling of time-varying log-hazard 
of pneumonia by influenza subtype. Finally, we defined 𝛽 to be a vector of hazard ratios, 
corresponding to their respective combination of age and sex, 𝑥𝑖. We then defined the rate of 
pneumonia for individual i on day t as: 
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Model 3: 
log(𝜆𝑖(𝑡)) =  𝜆0(𝑡) +  𝑥𝑖
′𝛽 + 𝐼(𝑠𝑖 > 0)𝑓(𝑡 − 𝜁𝑖 , 𝑠𝑖) 
Where 𝐼(𝑠𝑖 > 0) is an indicator variable evaluating to 1 if the individual was infected by any 
influenza subtype in the last 30 days, and 0 otherwise. We can then express this rate as the 
probability of pneumonia on any given day using the conditional log-log link function, i.e. 
Pr(𝑦𝑖𝑡 = 1) = 1 − exp (−𝜆𝑖(𝑡)), which allows the values of 𝜆0(t) and 𝛽 to be interpreted as a 
baseline hazard and hazard ratios respectively.[118] Additional details on the statistical analysis 
can be found in Appendix A 
3.5 Results 
 Between January 1, 2011 and December 31, 2018, 3234 children participated in the study 
(Table 3.2). The mean age at enrollment was 3.2 years (SD: 3.8), and mean follow-up time was 
3.7 years (SD: 2.5). The proportion of study participants withdrawn or lost to follow-up was low 
at 3.1% per year. The most common reasons for early withdrawal/removal from the study were 
not meeting the requirements of the annual sampling routine (54.8%) and inability to locate the 
participant’s home (23.2%). A total of 12 (0.4%) participants died during the study. Pneumonia 
was listed on the death certificate as a cause of death for 8 (66.7%). While seasonal influenza 
vaccination in the cohort was low averaging 3.2% (range: 0.7, 7.7%) of participants per year, 
Oseltamivir was relatively common, being used in 41.0% of influenza episodes. Antibiotics were 
provided in 27.1% of total clinic visits and 26.1% of clinic visits associated with an influenza 
episode. 
 There were 1199 cases of clinical pneumonia (Table 3.2, Figure 3.2), of these 226 
(18.9%) required hospitalization. Pneumonia cases were more likely to occur in children who 
were younger and male, with nearly 60% of pneumonia cases in males and over 70% in children 
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aged <2 years (Table 3.2). Pneumonia cases among infants (< 1 year) more frequently required 
hospitalization than those among participants aged 5-14 years (28.6% vs. 4.4%).  
 Among clinical pneumonia cases, 62 (5.2%) had RT-PCR confirmed influenza infection 
in the 30 days preceding pneumonia diagnosis. Of these, 21 (33.9%) were A/H3N2, 24 were 
A/H1N1pdm09 (38.7%), and 17 (27.4%) were influenza B. Pneumonia episodes following 
A/H1N1pdm09 were more often severe, with 25.0% requiring hospitalization compared with 
4.8% and 5.9% for H3N2 and influenza B respectively (p =0.08). Primary pneumonia was more 
common than secondary pneumonia following influenza with 40 (64.5%) pneumonia cases 
occurring within 0-6 days following influenza vs. 22 (35.5%) cases occurring ≥7 days following 
influenza (p=0.01). Primary pneumonia occurred an average of 2.1 (s.d.: 1.5) days after influenza 
symptom onset compared to 18.8 (s.d.: 7.4) days for secondary pneumonia. We observed no 
difference in the severity of primary and secondary pneumonias with 12.8% and 13.0% of each 
group respectively (p=0.98) being hospitalized.  
 For participants with a laboratory confirmed influenza infection the matched odds ratio 
(mOR) of developing clinical pneumonia in the 30 days post influenza onset were 2.7 (95% 
confidence interval [CI]: 1.9, 3.9) times that of children without influenza (Table 3.3). Sex-
specific effects were also observed, with male participants’ odds of developing pneumonia 1.6 
(95% CI: 1.4, 1.8) times that of females. For every 1000 infants with symptomatic influenza 
there were 36.3 (95%CI: 17.9, 60.0) excess pneumonia cases among males, and 26.2 (95% CI: 
11.9, 43.8) excess cases among females (Table 3.4). The overall number of excess cases per 
1000 symptomatic influenza infections among children under 5 years of age was 17.4 (95% CI: 
8.4, 28.7) for males, and 12.7 (95% CI: 6.0, 21.4) for females. 
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3.5.1 Influenza subtype and subsequent pneumonia 
 Examined by subtype (Model 1), those with symptomatic H1N1pdm09 infections had the 
highest odds of developing clinical pneumonia in the subsequent 30 days, 3.7 (95% CI: 2.0, 6.9) 
times that of participants without influenza illness. Those with symptomatic H3N2 or influenza 
B infection also had greater odds of developing pneumonia, specifically 2.1 (95% CI: 1.2, 3.7) 
and 2.7 (95% CI: 1.5, 5.2) times that of participants without influenza respectively.  
 Similarly, the time-to-event model (Model 3), indicated an increased hazard of clinical 
pneumonia in the 30 days following symptomatic influenza infection (Figure 3.3). Hazard ratios 
were highest for H1N1pdm09, followed by Influenza B, and then H3N2 (Figure 3.3). The 
relationship between symptomatic influenza and clinical pneumonia was largely consistent 
across participants aged 0-5 (regardless of subtype) but became difficult to distinguish among 
older participants (> 7 years) because of sparse data. As such, results reported from model 3 are 
limited to those aged ≤7 years (Figures 3.4 and 3.5). While the HRs remained relatively 
consistent from age 0-5, incidence decreased sharply as age increased, particularly beyond 2 
years (Figures 3.4 and 3.6).  
3.5.2 Risk period for clinical pneumonia following influenza 
 Model 2 assessed the risk period for clinical pneumonia following any symptomatic 
influenza infection in the matched case control study. Participants with symptomatic influenza 
infection had substantially higher odds of developing pneumonia in the 30 days post-influenza 
when compared to participants without symptomatic influenza. Specifically, the relative odds of 
pneumonia were highest in the first (0-6 days), and third weeks (14-20 days) following 
symptomatic influenza infection. Participants with symptomatic influenza had 8.3 (95% CI: 4.8, 
14.5) times higher odds of developing pneumonia in the week following infection, and 2.5 (95% 
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CI: 1.1, 5.5) times higher odds of developing pneumonia in the third week following infection 
(Table 3.5) compared to participants without symptomatic influenza, a pattern similar to that 
observed in the survival model (Model 3). For each subtype, an initial peak in relative hazard of 
clinical pneumonia was observed during the first week following influenza illness, though its 
magnitude varied by subtype. Additionally, H1N1pdm09 displayed a secondary peak of 
pneumonia hazard beginning around the 3rd week post infection. While the confidence region did 
include the null value, the magnitude closely matches the OR for the corresponding period in 
model 2 (Figure 3.3 and Table 3.5).  
3.6 Discussion 
 We show that among children, symptomatic influenza infection is associated at the 
individual level with increased risk of pneumonia in the 30 days following illness onset. This 
association was observed across influenza subtypes (H1N1pdm09, H3N2, and B), and was 
stronger among young children. We also observed that pneumonia risk was not constant 
throughout the 30-days following symptomatic influenza infection, with distinct periods of 
elevated pneumonia risk 0-6, and 14-20 days following influenza illness onset. This suggests 
differing pathologies causing pneumonia, with primary pneumonias nearly concurrent with 
influenza, and secondary pneumonias after a 2-3 week lag.  
 Multiple studies have suggested that secondary bacterial pneumonia was a primary driver 
of mortality in influenza pandemics including those in 1918[68, 69] and 2009.[49, 70, 72] 
However, it is unclear whether this extends to inter-pandemic periods, or non-fatal secondary 
bacterial pneumonia. A 2000 matched case-control study found that cases of pneumococcal 
pneumonia were more likely to have reported influenza-like-illness (ILI) in the 7-28 days 
preceding hospital admission (mOR 12.4, 95% CI: 1.7, 306) than age-matched controls.[50] The 
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magnitude of this association decreased when influenza infection was determined using H1N1 
serology, but remained substantial (mOR 3.7, 95% CI: 1.0, 18.1). This is very similar to our 
estimate for H1N1pdm09 over a comparable timeframe of 30 days (mOR: 3.7, 95% CI: 2.0, 6.9). 
A South African study from 2016 reported prevalence of influenza-associated severe pneumonia 
and influenza-associated pneumonia requiring hospitalization as 20% and 33% respectively 
among children aged ≤ 2 years. [119] While our estimates for this age group were lower (14% 
severe, 19% hospitalized), this difference reflects a small variation in the absolute number of 
cases.  
 The proportion of Nicaraguan children who are age-appropriately vaccinated with PCV13 
is nearly 100%.[75] The burden of influenza-associated pneumonia observed in our study may be 
different from populations with lower PCV coverage where a greater number of secondary 
bacterial pneumonias would be expected. Additionally, pneumococcus is not the only cause of 
secondary bacterial pneumonias and given our use of clinical pneumonia we cannot therefore 
exclude the possibility that some secondary pneumonia cases resulted from other bacteria or 
even (non-influenza) viral infections.   
 Our observation that H1N1pdm09 was associated with greater risk of subsequent 
pneumonia compared to H3N2 may seem to contradict the widely accepted convention of more 
severe disease during H3N2-predominant seasons.  However, the differences that we found were 
not statistically significant beyond the first 3 days following infection.  Also, our models 
assessed the expected severity of illness given infection, which is different from disease 
frequency.   
 Exploring the relationship between viral respiratory infections and subsequent pneumonia 
is notoriously difficult to do at a participant level. A recent review of studies examining the 
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relationship between viral respiratory infection and subsequent pneumococcal disease found that 
nearly 90% of relevant studies were ecologic, substantially limiting causal inference.[109] 
Among the two participant-level studies of influenza and pneumonia, one was limited by 
seasonal confounding[51], while the other[50] was hampered by its small sample size (13 cases). 
Several large-scale studies exploring pneumonia etiology have recently published their results 
including PERCH[7], GABRIEL[120], EPIC[121], and the Drakenstein Cohort.[119] These 
studies have focused on assessing pathogens that are detectable upon diagnosis with pneumonia 
compared to non-pneumonia controls. However, none of these studies have yet examined the 
temporal dynamics of pneumonia following influenza.  
 This study has several strengths. First, data were obtained from a community-based 
prospective cohort, limiting the potential for reverse causation bias. Second, this study was 
conducted on a participant-level, allowing us to calculate individual-level hazard rather than 
population-level correlation. Third, this analysis involved a larger sample size than previous 
studies, improving power and precision of effect estimates. Fourth, seasonality of the exposure 
and outcome were accounted for in both the matched case-control and the prospective cohort. 
The consistency of trends observed in both the conditional logistic regression and survival 
models lends further support to the primary conclusions of this analysis.  
 This analysis did have some limitations. Influenza-associated pneumonia is a rare 
outcome, and categorization by subtype and lag-time between influenza and pneumonia only 
resulted in fewer cases per strata. This limited statistical power to assess variation in risk period 
for pneumonia by influenza subtype, as well as the number of covariates included in the model. 
As such, the existence of residual confounding is a possibility. However, we would not expect 
such residual confounding to affect the temporal relationship between pneumonia and influenza 
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as confounders would likely be constant over such a short time scale (30 days). While we did not 
examine other respiratory pathogens as potential causes of pneumonia, by accounting for 
calendar time the model captures such associations. This doesn’t account for co-infections 
between influenza and other respiratory pathogens (particularly RSV), but we would anticipate 
the effect of co-infections to be minimal as previous analyses have shown influenza/RSV co-
infections  rare in this population.[112] Perhaps the biggest limitation of this study is our use of 
clinical pneumonia to define cases rather than imaging and molecular diagnostics. While we 
were unable to definitively state whether a pneumonia case was viral or bacterial in origin, the 
importance of clinical pneumonia diagnosis shouldn’t be forgotten. Pneumonia diagnosis using 
IMCI criteria remains a widely utilized approach, particularly in LMICs. Even with more 
sophisticated diagnostics like RT-PCR, bacterial culture, and chest radiography, distinguishing 
between primary viral and secondary bacterial pneumonias is challenging.[61] Lastly, we were 
unable to determine exact date of pneumonia onset and instead used diagnosis date, however, as 
this corresponds with when the symptoms were severe enough to seek treatment, it is a 
reasonable measure of pneumonia. 
 Many important questions remain regarding the biological, social, and environmental 
factors that affect the relationship between influenza and pneumonia. We hope the results of this 
study highlight the importance of understanding the temporal dynamics between influenza and 
pneumonia. Further, we hope that increased collaboration and data sharing may facilitate the 
exploration of aspects of this relationship which studies to date have been underpowered to 
address. Regardless, it is clear that influenza remains an important driver of the global 
pneumonia burden, through both primary and secondary pneumonias. More effective tools to 
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prevent and treat influenza present promising mechanisms by which the burden of pneumonia 
can be reduced.
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Table 3.1: Clinical Pneumonia Case Definition Used by the Nicaraguan Ministry of Health 
Age   
< 2 months ≥ 60 breaths per minute 
2-11 months ≥ 50 breaths per minute 
12-59 months ≥ 40 breaths per minute 
≥ 60 months ≥ 25 breaths per minute 






Figure 3.1: Matching Scheme for Nested Matched Case-control Study 
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 N = 3234 N = 1199  
(683 
participants) 
N = 62  
(59 
participants) 
Age at enrollment in yearsb 3.6 (3.6) 0.5 (1.7) 0.6 (2.1) 
Person-years contributedb 3.7 (2.5) 4.5 (2.6) 4.8 (2.6) 
Male 1602 
(49.5%) 
702 (58.5%)c 34 (54.8%) c 
Smoking in household 998 
(31.3%) 
239 (35.0%) c 25 (42.4%) c 
Share a bed 1964 
(63.2%) 
475 (71.6%) c 44 (74.6%) c 
Mothers with secondary or tertiary education 2312 
(76.5%) 
506 (74.1%) c 46 (91.5%) c 
Fathers with secondary or tertiary education 2082 
(73.1%) 
464 (67.9%) c 38 (64.4%) c 
Age  <12 months .. 496 (41.4%) 22 (35.5%) 
  12-23 months .. 389 (32.4%) 20 (32.2%) 
  24-59 months .. 224 (18.7%) 14 (22.6%) 
  ≥60 months .. 90 (7.5%) 6 (9.7%) 
Required hospitalization .. 226 (18.9%) 8 (12.9%) 
Deemed severe pneumonia .. 176 (14.7%) 6 (9.7%) 
Primary pneumonia (0-6 days following 
influenza) 
.. .. 40 (64.5%) 
Secondary pneumonia (7-30 days following 
influenza) 
.. .. 22 (35.5%) 
Influenza type  H3N2 .. .. 21 (33.9%) 
  H1N1pdm09 .. .. 24 (38.7%) 
  Influenza B .. .. 17 (27.4%) 
aData reflect number(column %) unless otherwise specified 
bMean(SD) 




Figure 3.2:  Influenza and Clinical Pneumonia among Cohort Members 0-14 years, Nicaragua 
2011-2018 
The lines represent the number of cases of influenza A, influenza B, and clinical pneumonia per 





Table 3.3: Matched Odds Ratios of Developing Clinical Pneumonia Within 30 Days Following 
Symptomatic Influenza Infection by Gender and Influenza Subtype 
 Matched Odds 
Ratio (mOR) 
95% Confidence Interval p-value 
Male 1.6 (1.4, 1.8) <0.001 
Influenza 
(overall) 
2.7 (1.9, 3.9) <0.001 
Influenza A 2.7 (1.8, 4.1) <0.001 
A/H3N2 2.1 (1.2, 3.7) 0.008 
A/H1N1pdm09 3.7 (2.0, 6.9) <0.001 
Influenza B 2.7 (1.5, 5.2) 0.0018 





Table 3.4: Excess Cases of Pneumonia in Next 30 Days per 1000 Symptomatic Influenza 
Infections 
Age (years) Male Female 
< 5 17.4 (8.4, 28.7) 12.7 (6.0, 21.4) 
< 1 36.3 (17.9, 60.0) 26.2 (11.9, 43.8) 
1 24.0 (11.3, 40.3) 16.9 (8.1, 29.1) 
2 15.3 (7.3, 26.4) 10.9 (4.8, 18.5) 
3 9.8 (4.3, 17.3) 7.0 (2.4, 12.6) 
4 6.5 (2.6, 11.4) 4.5 (1.3, 8.2) 




Figure 3.3: Hazard Ratios for Pneumonia in the 30 days Following Influenza Infection Among 
Participants Aged < 5 Years 
The lines represent the relative hazard of pneumonia (model 3) in the 30 days following an 
influenza infection compared to those who had no influenza infection. The relative hazard of 
pneumonia for each influenza subtype can be distinguished by line type provided in the legend. 
The shaded areas reflect the 95% confidence intervals with those that are overlapping being 




Figure 3.4: Hazard Ratios for Pneumonia in the 30 Days Following Influenza and Subtype 





Figure 3.5: Hazard Ratios for Pneumonia in the 30 Days Following Influenza by Subtype Among 




Figure 3.6: Incidence Rate of Pneumonia per 1000 in the 30 Days Following Influenza Infection 







Table 3.5: Matched Odds Ratios of Developing Pneumonia in the 30 Days Following Influenza 
Infection by Week 





Male 1.6 (1.4, 1.8) <0.001 
Influenza 0-6 days prior 8.3 (4.8, 14.5) <0.001 
Influenza 7-13 days prior 0.9 (0.4, 2.3) 0.8 
Influenza 14-20 days prior 2.5 (1.1, 5.5) 0.03 
Influenza 21-30 days prior 0.9 (0.4, 2.0) 0.7 
aResults obtained from model 2 
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Chapter 4 Exploring the Risk Period for Pneumonia Following Symptomatic Influenza 
Infection Among Nicaraguan Children Before and After the Introduction of the 
Pneumococcal Conjugate Vaccine 
 
 
4.1 Author summary 
Participants with symptomatic influenza had greater odds of developing subsequent 
pneumonia in the subsequent 30 days when compared to participants without influenza. This was 
true for all influenza types/subtypes except the pre-pandemic strain of H1N1. The odds of 
developing pneumonia following infection with a specific influenza subtype were largely 
consistent across the pre- and post-PCV cohorts. The same was true of the risk period for 
pneumonia, with the odds of developing pneumonia highest in the first two weeks following 
influenza infection. The risk period was different than that described in Chapter 3 which may 
suggest an age effect we were underpowered to detect. 
4.2 Abstract 
 Influenza is associated with primary viral and secondary bacterial pneumonias; however, 
the dynamics of this relationship in populations with varied levels of pneumococcal vaccination 
remain unclear. We conducted nested matched case-control studies in two prospective cohorts of 
Nicaraguan children aged 2-14 years: one before PCV introduction (2008-2010) and one 
following its introduction and near universal adoption (2011-2018). The association between 
influenza and pneumonia was similar in both cohorts. Participants with influenza (across 
types/subtypes) had higher odds of developing pneumonia in the month following influenza 
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infection. These findings underscore the importance of considering influenza in interventions to 
reduce global pneumonia burden. 
4.3 Introduction 
Influenza is an important cause of pneumonia, with evidence suggesting that this occurs 
both directly via primary viral pneumonia and indirectly via secondary bacterial pneumonias 
caused by pathogens including Streptococcus pneumoniae and Staphylococcus aureus.[68, 69, 
77, 104] Globally, the introduction of pneumococcal conjugate vaccines has been associated with 
decreased pneumonia morbidity and mortality.[74, 75] However, the effect this might have on 
influenza-associated pneumonias requires examination.  
The pneumococcal conjugate vaccine (PCV13) was introduced to Nicaragua in December 
2010, and by the end of 2012, nearly 100% of children were appropriately vaccinated for their 
age.[75]  In this analysis, we conducted a nested, matched case-control study within a cohort of 
Nicaraguan children aged 2-14 years followed from June 2007-December 2010 to assess the risk 
period for influenza-associated pneumonias in a population largely unvaccinated for 
pneumococcus. We repeated these analyses within another cohort of children from the same 
community from January 2011-December 2018 (where PCV13 coverage was ~100% for 
children in the target age-groups) to describe the association between influenza and pneumonia 
before and after PCV13 was introduced. 
4.4 Methods 
4.4.1 Ethics statement 
This study is a collaboration between the Sustainable Sciences Institute, the Nicaraguan 
Ministry of Health, the University of California, Berkeley (UCB), and the University of 
 62 
Michigan (UM). The study was approved by the Institutional Review Boards (IRBs) of the 
Nicaraguan Ministry of Health, UCB, and UM. Written informed consent was obtained from a 
parent/guardian of all participants. Verbal assent was obtained from children aged ≥6 years. 
4.4.2 Study population and sample collection 
This analysis used data from two prospective cohort studies of Nicaraguan children aged 
2-14 years.[111, 122] The first, conducted from June 2007 through 2010, is hereafter referred to 
as the pre-PCV cohort, and the second, conducted from January 2011 through 2018, is hereafter 
referred to as the post-PCV cohort.  The methods of both studies have been described in detail 
previously.[111, 122] Briefly, participants were enrolled from District II of Managua, Nicaragua, 
at Health Center Sócrates Flores Vivas (HCSFV). A detailed sociodemographic survey was 
collected upon enrollment and yearly thereafter for the duration of the child’s participation. A 
clinical history was also collected on enrollment and was updated any time the child came to the 
HCSFV. Healthcare was provided to all study participants, and study nurses and physicians were 
available at the HCSFV 24 hours/day, 365 days/year. Parents agreed to bring their child to the 
clinic any time they were sick, and in particular, when they had a recorded fever or were 
“feverish.”  
Upon presenting at the study clinic, participants were assessed for influenza-like illness 
(ILI) defined as: fever or reported fever and rhinorrhea, cough, or sore throat. In the pre-PCV 
cohort, respiratory samples for influenza testing were obtained from a random sample of 25% of 
participants presenting with these symptoms using nasal and oropharyngeal polyester-tipped 
plastic swabs.[122] In the post-PCV cohort, samples were obtained from all participants meeting 
the testing criteria.[111] Episodes of clinical pneumonia were diagnosed by study physicians 
using guidelines based on the Integrated Management of Childhood Illness (IMCI).[113] 
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Pneumonia onset was considered to be date of diagnosis, while the start of symptoms reported 
with an influenza-positive episode was considered to be the date of influenza onset. 
4.4.3 Laboratory methods 
The QIAamp Viral RNA Mini Kit (Qiagen) was used to extract RNA from swabs, which 
was then tested for influenza A and B by RT-PCR following the Centers for Disease Control and 
Prevention (CDC) protocol. Samples positive for influenza A were subtyped (H3N2, H1N1, or 
H1N1pdm09). Samples were not routinely tested for other pathogens. 
4.4.4 Statistical analysis 
Cases of clinical pneumonia were matched on age (months) and week of study to up to 
four controls in their respective cohorts. Participants with no episodes of clinical pneumonia in 
the previous 45 days were eligible to serve as controls.  
Conditional logistic regression models were fit to assess the relative odds of clinical 
pneumonia in the 30 days post-influenza. Separate models were fit to examine the relationship 
between influenza subtype and subsequent pneumonia (model 1), and the time-lag (0-6 days, 7-
13 days, 14-29 days) between influenza and pneumonia (model 2) to ensure sufficient power.  
Since only a random sample of pre-PCV cohort participants were tested for influenza, 
some influenza-positive participants may have been misclassified as influenza-negative. To 
achieve unbiased estimates, we repeated the previously described models with 100 complete 
datasets using multiple imputation methods described by Keogh et al.[123] Influenza subtype 
was imputed within each matched set for those who met the testing criteria and weren’t sampled. 
Imputation models were fit using logistic or multinomial regression (if >1 subtype circulated) 
with sex and ILI as predictors. Age and seasonality were accounted for by conducting the 
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imputation within each matched set. All analyses were conducted using R version 3.6.3. 
Additional information regarding the statistical methods can be found in Appendix B. 
4.5 Results 
A total of 4517 and 2731 children participated in the pre-PCV and post-PCV cohorts, 
respectively. No participants were vaccinated for pneumococcus in the pre-PCV cohort, while 
nearly 100% of participants enrolled before their 2nd birthday into the post-PCV cohort were 
vaccinated with PCV13.  Influenza vaccination also occurred in the post-PCV cohort, but at very 
low levels (<1% per year). 
There were 1117 episodes of clinical pneumonia that occurred in the pre-PCV cohort and 
314 in the post-PCV cohort (Tables 4.1, 4.2 and Figure 4.1). This disparity remained after 
standardizing the age distributions for comparison, with the incidence rate of all-cause 
pneumonia in the pre-PCV cohort 3.4 times that of the post-PCV cohort (Table 4.5). A greater 
proportion of all-cause pneumonias in the post-PCV cohort required hospitalization compared to 
the pre-PCV cohort (13.1% vs. 1.7%, p = <0.0001). However, the opposite was true for 
pneumonias occurring within 30 days of laboratory-confirmed influenza. In the pre-PCV cohort, 
10.3% of influenza-associated pneumonias required hospitalization, while none in the post-PCV 
cohort required hospitalization (p=0.3). 
Of the 1117 episodes of clinical pneumonia in the pre-PCV cohort, 39 (3.5%) were 
considered influenza-associated. There were 3 influenza A subtypes that circulated in the 
population during the study period (H3N2, H1N1, and H1N1pdm09), along with influenza B. 
H1N1pdm09 was most frequently associated with clinical pneumonia with 15 episodes (38.5%), 
followed by influenza B with 12 episodes (30.8%), H3N2 (9 episodes, 23.1%), and H1N1 (3 
episodes, 7.7%).   
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There were 21 (6.7%) episodes of influenza-associated pneumonia in the post-PCV 
cohort. Influenza B was the most commonly observed with 9 (42.9%) episodes, followed by 
H3N2 and H1N1pdm09, each with 6 (28.6%) episodes.  
4.5.1 Influenza subtype and subsequent pneumonia 
In both the pre- and post-PCV cohorts, participants with symptomatic H3N2, influenza B, 
or H1N1pdm09 infections displayed higher odds of pneumonia in the 30 days following 
influenza onset compared to participants without influenza illness (Table 4.3). Odds of 
subsequent pneumonia associated with specific influenza types/subtypes were similar in both the 
pre- and post-PCV cohorts. The importance of male sex differed between the cohorts, as it was 
associated with 30% higher odds of developing pneumonia in the post-PCV cohort, but showed 
no difference in the pre-PCV cohort.  
4.5.2 Characterizing the risk period for pneumonia following influenza 
We also examined how the odds of pneumonia following symptomatic influenza changed 
over time, specifically in the periods 0-6, 7-13, and 14-29 days following influenza onset. In the 
pre- and post-PCV cohorts, we observed the greatest odds of pneumonia in the first 0-6 days 
after influenza (Table 4.4). The odds that participants with any symptomatic influenza infection 
would develop pneumonia in the first 0-6 days were 11.3 times (95% CI: 5.0, 25.4), and 63.8 
times (95% CI: 8.2, 498.5) that of participants without influenza in the pre- and post-PCV 
cohorts respectively. We observed similarly elevated odds of pneumonia in the 7-13 days 
following influenza in both cohorts, specifically 4.1 times (95% CI: 1.3, 13.1) and 9.6 times 
(95% CI: 1.2, 75.1) that of participants without influenza in the pre- and post-PCV cohorts.  
Finally, for the period 14-29 days post-influenza, which we hypothesize to be the risk period for 
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bacterial pneumonia, the mOR in each cohort were similar, and slightly but non-significantly 
greater than 1 (Table 4.4). 
4.6 Discussion 
In this study, we described the risk period for developing clinical pneumonia following 
symptomatic influenza infection within cohorts of Nicaraguan children both before and after the 
introduction of pneumococcal conjugate vaccines (PCV). Notably, we did not observe a 
difference in the odds of developing pneumonia in the 30 days post-influenza following the 
introduction of PCV13. There were, however, substantially more episodes of pneumonia in the 
pre-PCV cohort. Influenza-associated pneumonia episodes also tended to be more severe in the 
pre-PCV cohort, with 10.3% requiring hospitalization compared to 0% in the post-PCV cohort.  
The literature exploring the risk period for pneumonia following influenza at an 
individual level remains limited. A 2018 review by Li et al. found only two individual-level 
studies exploring pneumococcal disease following influenza, and both had substantial 
limitations.[50, 51, 109] A matched case-control study from 2000 reported that patients 
hospitalized with severe pneumonia were more likely to have positive convalescent serology 
(titer ≥ 1:40) for H1N1 than non-ill controls (mOR: 3.7, 95% CI:1.0, 18.1).[50] While we did not 
see a significant association between H1N1 and subsequent pneumonia, this difference may be 
attributable to our use of RT-PCR for influenza diagnosis, a more reliable indicator of acute 
infection than convalescent serology.  
We recently published an analysis assessing the risk period for pneumonia following 
influenza in a broader cohort of Nicaraguan children from which the post-PCV cohort in this 
analysis was drawn.[124] The only difference is that in this analysis, children aged <2 years were 
excluded to make the pre- and post-PCV cohorts comparable. In that analysis, we similarly 
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observed that influenza, regardless of type/subtype, was associated with increased risk of 
developing pneumonia in the next 30 days. There were some (non-significant) differences in 
which subtype was associated with the highest risk of pneumonia, and in the apparent time-trend 
of pneumonia risk. This may suggest that the risk period differs for children aged <2, as the 
majority of influenza-pneumonia cases in our previous analysis occurred in this age group. 
However, the wide and overlapping confidence intervals also indicate we are underpowered to 
conclusively identify such differences.  
This study has several strengths. First, as a case-control study nested within a prospective 
cohort, we were better able to ensure temporality between exposure and outcome. Second, while 
power limitations remained a challenge given the rarity of the outcome, this analysis had a larger 
sample size than much of the literature exploring the risk period for pneumonia following 
influenza, particularly at an individual level. Third, both cohorts were enrolled from the same 
Nicaraguan community (i.e., base population). This provided a unique opportunity to describe 
the nature of the influenza/pneumonia association both before and after the vaccine was 
introduced. Fourth, our use of multiple imputation to account for incomplete exposure 
ascertainment provides a reasonable approximation of the unbiased association between 
influenza and pneumonia in the pre-PCV cohort. 
This study also has some limitations. First, in the pre-PCV cohort, not all participants 
presenting to the study clinic and meeting the sampling criteria were tested for influenza. Instead, 
a 25% random sample was obtained. However, through multiple imputation and additional bias 
analysis, we were able to confirm that our imputed values fell within the bounds of what we 
would expect for the unbiased estimate (Table 4.6). Second, as pneumonia is a rare outcome, 
sparse data limited the covariates we were able to include in our models. Third, our analysis did 
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not include children aged <2 years, the pediatric age group with the greatest burden of 
pneumonia. Finally, use of symptom-based criteria for clinical pneumonia to define cases limited 
our ability to make definitive distinctions between viral and bacterial etiologies. However, this is 
a common problem in pneumonia diagnosis, even with diagnostics like chest radiography or 
PCR.[61, 69]  
In this analysis, we observed that influenza substantially increased the odds of pneumonia 
in the subsequent 30 days, and that the risk period for pneumonia following symptomatic 
influenza infection among children was similar before and after PCV13 was introduced to 
Nicaragua. This further underscores the importance of influenza in considering how best to 
reduce the global burden of pneumonia. 
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Table 4.1: Characteristics of Participants and Pneumonia Cases in the Pre-PCV Cohort 











Age at enrollment (years)b 6.0 (2.9) 4.3 (2.5) 4.5 (2.6) 
Person-years contributedb 3.0 (0.9) 3.0 (0.8) 3.2 (0.6) 
Male  2274 (50.3) 392 (51.9) 13 (33.3) 
Age 24-59 months -- 545 (48.7) 14 (35.9) 
 ≥ 60 months -- 574 (51.3) 25 (64.1) 
Required 
hospitalization 
 -- 19 (1.7) 4 (10.3) 
     
Primary 
pneumoniac 
 -- -- 25 (64.1) 
Secondary 
pneumoniad 
 -- -- 14 (35.9) 
Influenza type H3N2 -- -- 9 (23.1) 
 H1N1 -- -- 3 (7.7) 
 H1N1pdm09 -- -- 15 (38.5) 
 Influenza B -- -- 12 (30.8) 
Data reflect number (column %) unless otherwise specified 
aColumn % reflects the number of participants 
bMean (SD) 
cWithin 7 days of influenza onset 




Table 4.2: Characteristics of Participants and Pneumonia Cases in the Post-PCV Cohort 











Age at enrollment (years)b 4.6 (3.2) 2.0 (2.8) 2.0 (3.2) 
Person-years contributedb 4.2 (2.7) 5.3 (2.3) 5.7 (2.3) 
Male   126 (54.1%) 8 (42.1%) 
Age 24-59 months -- 224 (71.3%) 15 (71.4%) 
 ≥ 60 months -- 90 (28.7%) 6 (28.6%) 
Required 
hospitalization 
 -- 41 (13.1%) 0 (0%) 
     
Primary 
pneumoniac 
 -- -- 14 (66.7%) 
Secondary 
pneumoniad 
 -- -- 7 (33.3%) 
Influenza type H3N2 -- -- 6 (28.6%) 
 H1N1pdm09 -- -- 6 (28.6%) 
 Influenza B -- -- 9 (42.9%) 
Data reflect number (column %) unless otherwise specified 
aColumn % reflects the number of participants 
bMean (SD) 
cWithin 7 days of influenza onset 









Table 4.3: Comparing Matched Odds Ratios (mOR) of Developing Pneumonia in the 30 Days 
Following Symptomatic Influenza Infection Among Nicaraguan Children Aged 2-14 Years 
 Pre-PCV a Post-PCV 
 Crude analysis Imputation analysis 
 mOR 95% CI mOR 95% CI mOR 95% CI 
Male 1.0 0.8, 1.1 1.0 0.98,1.0 1.3 1.0, 1.7 
Influenza 
(overall) 
4.2 2.6, 6.7 6.3 5.4,7.3 8.5 3.9, 18.9 
Influenza A 3.5 2.0, 6.1 5.0 4.1,6.1 8.1 2.8, 23.7 
A/H3N2 7.3 1.8, 29.6 9.3 3.4, 34.0 23.6 2.7, 204.7 
A/H1N1pdm09 5.3 2.4, 11.5 6.4 5.2, 13.5 5.2 1.5, 18.1 
A/H1N1  1.0 0.3, 3.7 1.3 0.6 2.7 --b --b 
Influenza B 5.3 2.2, 12.7 11.7 6.7, 20.6 9.0 2.8, 29.4 
a2007 excluded from analysis, see Appendix B 




Table 4.4: Assessing the Risk Period for Pneumonia in the 30 Days Following Symptomatic 
Influenza Illness Among Children Aged 2-14 Years 
 Pre-PCV a Post-PCV 
 Crude analysis Imputation analysis 
 mOR 95% CI mOR 95% CI mOR 95% CI 
Male 1.0 0.9, 1.2 1.0 0.99,1.01 1.4 1.0, 1.7 
0-6 days  11.3 5.0, 25.4 13.6 10.0, 18.4 63.8 8.2, 498.5 
7-13 days 4.1 1.3, 13.1 5.9 3.2, 11.1 9.6 1.2, 75.1 
14-29 days 1.5 0.7, 3.4 1.2 0.7,1.9 1.9 0.5, 6.6 





Table 4.5: Age Standardized Incidence Rates of Clinical Pneumonia 
 Pre-PCV cohort Post-PCV cohort 
 Incidence Rate 95% CIb Incidence Rate 95% CIb 
Pneumonia 9.3 8.6, 9.7 2.7 2.5, 3.1 
aAge distribution of post-PCV cohort used as reference for standardization 










 Lower bounda Multiple imputation Upper boundb 
 mOR 95% CI mOR 95% CI mOR 95% CI 
Male 0.99 0.9, 1.1 1.0 0.98, 1.0 0.99 0.8, 1.2 
Influenza 
(overall) 
4.2 2.6, 6.7 6.3 5.4, 7.3 22.1 17.6, 27.7 
Model 2 Male 1.0 0.9, 1.2 1.0 0.99, 1.01 0.99 0.8, 1.2 
0-6 days  11.3 5.0, 25.4 13.6 10.0, 18.4 56.8 40.3, 80.0 
7-13 days 4.1 1.3, 13.1 5.9 3.2, 11.1 20.3 13.7, 30.1 
14-29 days 1.5 0.7, 3.4 1.2 0.7,1.9 3.4 2.3, 5.0 
aAssumed those with ILI who were not sampled/tested were influenza negative 
bAssumed those with ILI who were not sampled/tested were influenza positive 
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Chapter 5 Knowledge Added and Future Directions 
 
A key principle of responsible research is to pursue questions that add to the collective 
knowledge in a given area. This is particularly important in epidemiology where research 
advances have the potential to dramatically improve health and well-being in society. In this 
chapter I will discuss what knowledge was contributed by my dissertation research and discuss 
avenues that may be pursued in future research. 
5.1 Aim 1 
In chapter 2 we aimed to answer some of the most basic questions concerning the burden 
of RSV illness among children in Nicaragua. While RSV’s important role in driving morbidity 
and mortality among young children has been repeatedly demonstrated [2, 7], substantial 
knowledge gaps remain.[27, 125, 126] RSV studies have largely been centered in hospital 
settings and high-income countries. Accurately characterizing the burden within communities 
and addressing geographic disparities is crucial to understanding the true scale of RSV’s 
effects.[2] Prior to this study, our understanding of RSV in Nicaragua was largely anecdotal, and 
quite limited in scope. In describing the burden of RSV within a prospective birth cohort we 
were able to address three fundamental questions related to RSV in Nicaragua.  
First, we were able to describe the relationship between age and incidence rates of RSV 
and RSV-associated severe illnesses like pneumonia and bronchiolitis. While children aged 6-11 
months had the highest incidence of symptomatic RSV, the incidence of severe RSV peaked 
among those aged < 3 months and declined as age increased (Tables 2.3 and 2.5, Figures 2.2 and 
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2.4). This differed from estimates reported in other LMICs where the highest incidence of both 
RSV and severe RSV were generally among children aged < 6 months (Table 2.7). It was, 
however, consistent with other estimates from Latin America—particularly Guatemala.[35] A 
second key question we were able to explore was that of RSV seasonality in Nicaragua. Though 
transmission occurred year-round, there were regular, yearly periods of epidemic transmission 
(Figure 2.3). This has critical implications for the design of future vaccination campaigns—once 
a vaccine is developed. It can also help identify which children are at increased risk for severe 
RSV illness because of the timing of their birth. Third, and perhaps most striking, was RSV’s 
role in driving infant mortality in the cohort. While the specific criteria used to attribute deaths to 
RSV remains a subject of debate [92, 96], at least 25% of illness deaths among cohort 
participants were associated with RSV infection. Though this represents a small proportion of the 
cohort, it is suggestive of a substantial burden in the base population from which the study was 
sampled.  
The results of this analysis provide a strong foundation on which to continue building our 
knowledge of RSV in Nicaragua and other LMICs. Further, it emphasizes the importance of 
considering RSV prevention and mitigation in the continued efforts to reduce infant mortality. 
These efforts will hopefully soon be aided by the introduction of new preventatives, therapeutics, 
and even a vaccine. Still, there remain important questions regarding RSV in Nicaragua that have 
yet to be explored. 
While Aim 1 characterized the burden of RSV and its severe manifestations, it did so for 
a relatively narrow age group—children under 2. This age group is of crucial importance given 
their greater frequency of severe RSV-associated illness, but it is far from the only group 
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affected. An important next step will be to describe the burden of RSV among older children and 
the elderly, providing a more comprehensive picture of the RSV burden in Nicaragua. 
Our understanding of RSV seasonality is also incomplete as it has only been assessed 
over a small number of years. While we confirmed yearly periods of epidemic RSV 
transmission, assessing this trend over longer time scales will provide important data on how 
these seasonal epidemics may vary from year to year. Fortunately, continued RSV testing 
through other cohort studies in the same population will provide this additional data and will 
help more accurately characterize the seasonal patterns of RSV transmission in Nicaragua and 
Latin America as a whole.  
There are also more specific questions that our general exploration of RSV burden did 
not address, particularly the burden of RSV subtypes and the dynamics of repeat infection. 
Future RSV testing to distinguish between RSV-A and -B could provide important insights 
related to subtype variability in transmission, illness severity, and even immunity, all of which 
would be helpful in informing the implementation of a future vaccine. Additionally, while we 
know that immunity to RSV is generally transient and allows for re-infection, we know very 
little about the frequency and risk factors associated with repeated RSV infection. By 
understanding what biological, social, and environmental factors may affect one’s risk of re-
infection we may be able to tailor prevention and mitigation efforts to those most at risk. 
Understanding such mechanisms may also inform implementation of a future vaccine by 
informing the need for (or timing of) booster doses.  
5.2 Aim 2 
In aim 2 of this dissertation we assessed the individual-level association between 
influenza and subsequent pneumonia and explored the temporal dynamics between them. While 
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the association between influenza and pneumonia has long been assumed, the evidence on which 
this assumption has been based largely on population-level correlations. Using a large 
prospective cohort of Nicaraguan children aged 0-14 years we were able to characterize the risk 
of developing pneumonia following symptomatic influenza infection at an individual level with 
precision not previously achieved.  
Through this analysis we observed that children with symptomatic influenza infection 
were at substantially higher risk of developing pneumonia in the subsequent 30 days, compared 
to those without influenza. This was true across subtypes although the magnitude of the risk 
differed (Table 3.3, Figure 3.3). We also observed two distinct periods of elevated pneumonia 
risk following influenza, specifically in the first and third weeks following influenza infection 
(Table 3.5). This suggests the presence of distinct etiologic pathways connecting influenza and 
pneumonia. Further, it fits well with the hypothesis of influenza being associated with both 
primary viral and secondary bacterial pneumonias, as we would expect viral pneumonias to 
occur soon after influenza, followed by secondary bacterial pneumonias after a delay.  
This analysis provides robust individual-level evidence of the association between 
influenza and pneumonia. This is important in its own right and could also help focus future 
studies and allow for greater precision in calculating effect estimates. Given the dearth of 
previous evidence we used relatively uninformed priors in our Bayesian survival model. Future 
studies of the relationship between influenza and pneumonia in new populations, can use more 
informed priors based on our results which may help to improve inferences. 
The results in aim 2 were an important first step in assessing the individual-level 
association and temporal dynamics between influenza and pneumonia. There are, however, 
several avenues through which this research can and should be continued and expanded. First, 
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the cohort study used in this analysis has continued, so there are years of additional data that can 
be analyzed. Though Aim 2 represents the largest individual-level study of this question to date, 
pneumonia remained a rare outcome which limited statistical power. Assessing the relationship 
between influenza and pneumonia within larger datasets will help to increase statistical power 
and improve precision. Aim 2 was also largely intended to provide a descriptive baseline upon 
which future research can be built. Assessing potential risk factors for pneumonia following 
influenza may help create more informed public health interventions. Similarly, identifying 
factors that modify a child’s risk period for pneumonia following influenza may help us better 
understand the mechanisms driving such an association. Finally, influenza is far from the only 
respiratory virus that has been linked with pneumonia. Characterizing the risk and temporal 
trends of pneumonia following viruses like RSV, human metapneumovirus, and now SARS-
COV-2, is essential if we are to continue to reduce the burden of pneumonia worldwide. 
5.3 Aim 3 
In Aim 3 of this dissertation, we described the individual-level association between 
influenza and pneumonia within two cohorts of Nicaraguan children aged 2-14 years. One cohort 
was from before pneumonia conjugate vaccines were introduced to the country (pre-PCV), and 
the other after their introduction and near-universal adoption (post-PCV). By exploring this 
relationship in additional populations we continued to expand the published evidence in this 
important area and added further support to the findings from aim 2.  
Much like aim 2 we conducted a nested matched case-control study in each cohort 
matching on age (months) and calendar time (study week) to account for confounding by age and 
seasonality. Conditional logistic regression models were fit to assess the odds of developing 
subsequent pneumonia after infection with specific influenza subtypes and how the odds of 
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pneumonia changed over time following influenza infection. In the pre-PCV cohort we also 
contended with incomplete exposure ascertainment as only a 25% random sample of children 
meeting the testing criteria were sampled/tested for influenza. However, using multiple 
imputation and additional sensitivity analyses we were able to estimate a reasonable 
approximation of the unbiased effect measures along with their upper and lower bounds (Table 
4.5).  
We again observed that influenza was associated with increased odds of developing 
pneumonia in the subsequent 30 days. This was true for all subtypes except for seasonal 
influenza A/H1N1. We also assessed the risk period for pneumonia following influenza, 
however, three time periods (0-6 days, 7-13 days, >13days post influenza) were used to assess 
the risk-period (instead of the four used in chapter 3) because of sparse data in the post-PCV 
cohort. Even so we can see some important differences in the results we observed in aim 2. 
Namely we saw significantly higher odds of developing pneumonia in the second week 
following influenza while we observed no such increased risk in this period in aim 2 (Tables 3.5 
and 4.4). This elevated risk of pneumonia in the 2nd week following influenza illness was 
observed in both the pre- and post-PCV cohorts suggesting that the difference in observed risk 
periods may result from an age effect that we were underpowered to detect. The post-PCV cohort 
in aim 3 is after all simply a subset of the aim 2 cohort excluding those aged < 2 years to allow 
comparability to the pre-PCV cohort.  
Aim 3 also explored the relationship between influenza and subsequent pneumonia, so 
many of the future research directions described for Aim 2 also apply. Identifying key risk 
factors for pneumonia following influenza, or those that affect the risk period could be 
particularly useful. Improving statistical power by increasing sample size and characterizing the 
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risk period for pneumonia following other viral infections is also important but would require use 
of data beyond the pre-PCV cohort. Still, the results of this analysis raise questions that should 
be explored further. While the risk period for pneumonia following influenza appeared largely 
similar in both the pre- and post-PCV cohorts we cannot unequivocally state that potential 
differences do not exist. It also remains unclear whether age may affect the risk period for 
pneumonia following influenza. Comparisons between the results from Aim 2 and the post-PCV 
cohort of Aim 3 would seem to suggest this, but we are underpowered to say so definitively. 
Considering the many populations with relatively low coverage of pneumococcal vaccines, it 
will be important to consider the relationship between influenza and pneumonia within 
populations that have different levels of vaccination.  
5.4 Conclusions 
In this dissertation we aimed to address some fundamental questions relating to RSV 
burden among Nicaraguan children, and to begin characterizing the relationship between 
influenza and subsequent pneumonia. By describing the incidence of RSV and the severe 
illnesses associated with it we added knowledge regarding its effects on a population particularly 
susceptible to it. In doing so we highlighted its importance in considerations of how to continue 
to reducing morbidity and mortality associated with acute respiratory infections. By describing 
the association between influenza and pneumonia within multiple prospective cohorts of 
Nicaraguan children we provided much needed individual-level data on the both the magnitude 
of the association and its timing. Such knowledge helps improve our understanding of the 
complex mechanisms that lead to severe respiratory illnesses like pneumonia. Each of these aims 
has opened new avenues of research to be pursued and it is our hope and belief that these results, 






Appendix A: Supplemental Methods for Chapter 3 
 
All statistical analyses were conducted using R version 3.6.1(R Foundation for Statistical 
Computing). Specifically the brms and stan packages were used for the Bayesian analysis, the 
survival package was used to run the conditional logistic regression models, and ggplot2 and 
tidybayes were used to create figures.[114-117] 
Statistical Model 
Here, we will describe a model to predict the risk of clinical pneumonia following 
influenza as a function of an observed time-varying background log-odds of pneumonia, denoted 
as 𝛾(𝑡), log odds ratios 𝛽. We can then define the hazard of influenza-associated pneumonia for 
individual 𝑖 at time 𝑡 as: 𝑙𝑜𝑔(𝜆𝑖𝑡) = 𝑙𝑜𝑔(ℎ(𝐱𝑖𝑡; 𝑡)) = 𝛾(𝑡) + 𝐱𝑖𝑡′𝛽. 
Preparing the data 
Each individual i has a vector of covariates associated with his/her observation. These 
include sex, age at the time of observation, number of days following influenza infection, etc. To 
simplify fitting of the model without increasing the computational burden, we can take advantage 
of the fact that each vector of covariates is not unique, i.e. that it may be shared by multiple 
individuals. So, for every possible combination of covariates, denoted by the set 𝐗, we count up 
the number of matching vectors 𝑥𝑖 in the original dataset. We denote 𝐱𝐣 to be the vector 
corresponding to covariate combination 𝑗, 𝑁𝑗 to be the number of observations 𝑥𝑖 = 𝑥𝑗, and 𝑦𝑗 to 
be the number of cases of clinical pneumonia among individuals with parameters 𝑥𝑗. This is 




To fit the model to the data prepared as described in the section above, we define the 
probability of pneumonia for individuals with covariate combination 𝑗 as 𝑝 = 1 − 𝑒𝑥𝑝(−𝜆𝑖𝑡) 
where 𝜆𝑖𝑡 = 𝑒𝑥𝑝(𝛾(𝑡𝑗) + 𝐱𝑗
′𝛽𝑗), and then model the probability of observing 𝑦𝑗 clinical 
pneumonia among the 𝑁𝑗 individuals with parameters 𝜃𝑗  as 𝑦𝑗 ∼ Binomial(𝑁𝑗, 𝑝𝑗). This is the 
equivalent of using a complementary log-log (cloglog) link function. Using the cloglog link 
allows for the calculation of hazard ratios from the model. 
Defining the model in brms 
To estimate the model defined above in brms, we first expand each participant interval in 
the original data into a long-form dataset showing days of participation in study. Using dplyr, we 
group by unique combinations of covariates and time periods (calendar time and time exposed), 
and then sum up the total number of individuals in each group, as well as the total number of 
clinical pneumonia cases. 
Using the cloglog link we can employ the linear syntax in brms as follows: 
we can define the likelihood in terms of the covariates impacting the log-hazard (in this case just 
denoted lambda), and then translate this into the value of 𝑝𝑖𝑡 needed to estimate the probability of 
observing 𝑦𝑗𝑡 pneumonia cases among the 𝑁𝑗𝑡 susceptible individuals in the cohort on that day 
with parameter combination 𝑗: 
model_f3 <- bf(pneumo_tot|trials(tot_exposed) ~ 
                 offset(lde) + sexo + age_y + s(days_pflu_1, by = o_sub) + s(study_month)) 
 
In the code above, s(study_month) s(days_pflu_1, by = o_sub) instructs brms to use a 
spline to model smooth variation in clinical pneumonia rates as a function of study month and 
days post influenza. The inclusion of by = o_sub in the spline term for days post influenza tells 
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brms to condition fitting the spline term on an ordered factor variable, o_sub, for influenza type. 
This allows the smoothed rate of clinical pneumonia to both vary by subtype and avoid being 
applied to instances where participants did not have an influenza infection. Finally, offset (lde) 
functions as a measure of the log person time at risk per year, log(days_exposed/365). 
m3e <- brm(model_f3, 
           data = d_day, 
           chains = 4, 
           iter = 6000, 
           warmup = 3000, 
           family = binomial("cloglog"), 
           set_prior("normal(0, 1)", class = "b"), 












Appendix B: Supplemental Methods for Chapter 4 
 
Multiple imputation was performed within each matched set using the mice package in R. 
[127] These methods and example code have been described in detail in Keogh et al. 2018.[123] 
Influenza subtype was imputed separately for each year to restrict possible imputed values to 
those circulating that year. Subtypes that occurred rarely in a given season (<5% of influenza 
positives) were excluded as possibilities from the imputation due to insufficient data. The 2007 
influenza season was dropped from the imputed analysis as the imputation failed to converge for 
that year. In 2008 and 2010 when multiple influenza subtypes circulated in the population 
multinomial logistic regression was used as the imputation model. In 2009, when only 
H1N1pdm09 circulated, logistic regression was used as the imputation model.  
As an additional sensitivity analysis, we fit models where we assumed that any 
participant presenting with influenza-like illness was flu positive. This provided an upper bound 
for what the unbiased effect estimates could be, while the models where we assumed those 
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